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ABSTRACT 
Angiogenesis is defined as the growth of new blood vessels from preexisting vessels. 
Systematic regulation of angiogenesis could lead to new treatments of vascular diseases and 
cancer. As such, vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, 
offers a promising therapeutic target. Despite this promise, VEGF targeted therapies are not 
clinically effective for many pathologies, such as breast cancer. Thus, a better understanding of 
the VEGF network for regulating angiogenesis, along with identifying key nodes controlling 
angiogenesis within this network, are necessary to provide effective VEGF therapeutics. Systems 
biology, defined as applying experiment and computational modeling to understand a biological 
system, can readily define this VEGF-angiogenesis network. In this dissertation, I provide an 
overview of how computational systems biology has been used to provide basic biological 
insights into angiogenesis, explore anti-angiogenic therapeutic options for cancer, and pro-
angiogenic therapeutic options for vascular disease.  
Using systems biology, I have previously predicted that VEGFR1 acts as a predictive 
biomarker of anti-VEGF efficacy in breast cancer. Particularly, tumor endothelial cell 
subpopulations exhibiting high VEGFR1 levels result in ineffective anti-VEGF treatment. These 
high VEGFR1 subpopulations are characterized by a high amount of VEGF-VEGFR1 complex 
formation, and subsequently high VEGF-VEGFR1 internalization. The high VEGF-VEGFR1 
complex formation implies a possible VEGFR1 signaling role beyond its classically defined 
decoy status. In this dissertation, I introduce a computational approach that accurately predicts 
the cell response elicited via VEGFR1 signaling. I show that VEGFR1 promotes cell migration 
through PLCγ and PI3K pathways, and promotes cell proliferation through a PLCγ pathway. 
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These results provide new biological insight into VEGFR1 signaling and angiogenesis while 
offering a system for directing angiogenesis. 
Cell subpopulations expressing high VEGFR1 levels are characterized by a large amount 
of VEGF-VEGFR1 internalization. Thus, endocytosis may regulate VEGFR1 signaling; indeed, 
intracellular-based receptor signaling has recently emerged as a key component in mediating cell 
responses for receptor tyrosine kinases (RTKs). However, how endocytosis fundamentally 
mediates signaling for any RTK remains poorly defined. Understanding how endocytosis 
fundamentally directs intracellular receptor signaling requires receptor-specific endocytosis 
mechanisms to be delineated. This delineation requires identifying the signaling mechanisms 
common to all receptor types. To this end, I conduct a computational meta-analysis predicting 
endocytic compartment signaling across eight RTKs, and identify their common signaling 
mechanisms. I find that endocytic vesicles are the primary cell signaling compartment; over 43% 
total receptor phosphorylation occurs within the endocytic vesicle compartment for all eight 
RTKs. Conversely, all RTKs exhibit low membrane-based receptor signaling, exhibiting < 1% 
total receptor phosphorylation. Mechanistically, this high RTK phosphorylation within endocytic 
vesicles may be attributed to their low volume, which facilitates an enriched ligand 
concentration. The late endosome and nucleus are also important contributors to receptor 
signaling, where 26% and 18% average receptor phosphorylation occurs, respectively. 
Furthermore, nuclear translocation requires late endosomal transport; blocking receptor 
trafficking from late endosomes to the nucleus reduces nuclear signaling 96%. These findings 
can be applied to understand specific RTK signaling functions in terms of cell response, and 
optimize RTK therapeutics targeting endocytic pathways. 
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Overall, I reveal the role of VEGFR1 and its signaling mechanisms, which is essential 
information to the field of angiogenesis. This information advances angiogenesis therapeutics by 
identifying the VEGF-VEGFR1 signaling axis as an essential target. I identify the primary 
adapters that can be targeted to critically regulate VEGF-VEGFR1 signaling, and endocytic 
compartmentalization that can be targeted for tuning receptor signaling. Furthermore, the 
computational techniques I develop advance the field of systems biology by delineating the 
signal-to-response of receptor signaling, improving receptor investigation by allowing adapter 
phosphorylation and cell responses to be quantified simultaneously, in addition to 
compartmentalized receptor signaling. These computational techniques improve disease 
treatment by allowing optimal receptor signaling targets to be identified quickly. Additionally, 
unknown receptor signaling can be mapped from adapter phosphorylation to cell response. These 
computational techniques can be integrated into multiscale computational models to provide 
clinically relevant, patient-specific platforms for directing disease treatment. 
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CHAPTER 1 
INTRODUCTION 
Angiogenesis is the physiological process where new microvessels form from preexisting 
microvessels [1], [2]. Similarly, arteriogenesis is where new collateral arteries form from 
preexisting arteries [3], [4]. As angiogenesis and arteriogenesis are similar processes [4], albeit at 
different scales, I use either term interchangeably for the purpose of this chapter. Angiogenesis 
occurs in two different forms: sprouting or intussusceptive angiogenesis [1], [2]. Sprouting 
angiogenesis involves preexisting blood vessels to sprout and form new blood vessels. Sprouting 
angiogenesis is initiated by extracellular growth factor binding to endothelial cell surface 
receptors [5]. This ligand-receptor binding has dual action: 1) it initiates enzyme secretion from 
endothelial cells, which break down the basement membrane, and 2) it promotes directed 
endothelial cell migration and proliferation [5]. The migrating endothelial cells result in tube 
formation and fusion, which are stabilized by pericyte recruitment in microvessels, or smooth 
muscle cell recruitment in arteries, to result in new, functional blood vessels [1], [6]. The 
majority of current angiogenesis research focuses on sprouting angiogenesis, due to its 
prevalence in wound healing [7] and cancer progression [8]. 
Intussusceptive angiogenesis is the splitting of an existing blood vessel into two blood 
vessels [2], [9], [10]. Intussusceptive angiogenesis occurs by blood vessel walls continuously 
extending into the lumen, forming an intravascular pillar, which eventually splits a single tube 
into two tubes. Unlike sprouting angiogenesis, intussusceptive angiogenesis is ineffective at 
vascularizing regions lacking blood vessels, instead primarily adding additional vessels to 
regions already containing blood vessels [2], [9], [10]. Additionally, intussusceptive 
angiogenesis does not require endothelial cell migration or proliferation [10]. While 
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intussusceptive angiogenesis can be initiated by growth factor stimulation, it also results from 
mechanical stress produced by blood flow [11]. Intravascular pillars seem to specifically form at 
vessel bifurcations when hemodynamics are altered to cause high flow velocity, but low shear 
stress [12], [13]. As such, intussusceptive angiogenesis is difficult to regulate, as hemodynamics 
cannot be easily altered and requires invasive procedures [13]. Further research investigating 
chemical cues, including any mechanotransduction pathways activated through shear stress, is 
necessary to develop efficient, noninvasive methods for regulating intussusceptive angiogenesis. 
Sprouting and intussusceptive angiogenesis are both critical to normal physiological 
processes, such as wound healing and embryonic development. Moreover, over 70 diseases, 
including cancer and occlusive vascular disease, are angiogenesis dependent [14], [15]. In 1971, 
Judah Folkman hypothesized that tumor growth depends on angiogenesis initiated by a tumor-
angiogenesis factor [16]. This hypothesis was derived from studies showing that tumors only 
grow to a dormant state, at 2-3 mm in diameter, in the absence of neovascularization [17]–[19], 
tumor implantation induces endothelial cell proliferation [16], [20] and formation of new 
capillaries [21]–[23], and tumor growth is limited by the rate of endothelial cell proliferation 
[24], [25]. Since this hypothesis, many studies have been conducted to arrive at the current 
understanding of tumor angiogenesis: tumor cells promote sprouting angiogenesis to provide the 
necessary nutrients for further tumor growth and metastasis, reviewed in [15], [26], [27]. 
Inhibiting sprouting angiogenesis is therefore a promising approach to prevent transition of 
tumors from a benign to malignant stage [28], [29].  
In 2005, Rakesh Jain put forth an alternative hypothesis on tumor angiogenesis: rather 
than destroying tumor vasculature to deprive the tumor of oxygen and nutrients, anti-angiogenic 
therapies are most effective by normalizing the abnormal tumor vasculature to allow more 
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efficient drug delivery [30]. This hypothesis was derived from studies showing that tumor 
vasculature is structurally and functionally abnormal [31]–[33], that this structural abnormality 
impairs blood flow and compromises the ability for drug delivery to tumors [34]–[36], and that 
normalizing tumor vasculature allows drug delivery deeper into tumors to cause tumor regression 
[37]–[39]. Studies have continued to provide support for this hypothesis, reviewed in [40], [41]; 
a recent clinical trial shows that vascular normalization, measured by pericyte coverage, is 
associated with improved pathological response to the anti-angiogenic drug bevacizumab [42]. 
Understanding the mechanisms through which anti-angiogenic drugs normalize tumor 
vasculature, and optimizing treatment regimens to best regulate sprouting angiogenesis, is a 
primary challenge for preventing tumor angiogenesis and tumor progression [43], [44]. 
Occlusive vascular diseases stem from a lack of blood flow, resulting in tissue ischemia, 
loss of limb function, and death [45]. For occlusive vascular diseases, promoting either sprouting 
or intussusceptive angiogenesis to reestablish proper blood flow is therefore a promising 
approach to prevent tissue ischemia [46], [47]. Overall, the ability to control angiogenesis would 
allow for the prevention and treatment of pathologies: preventing cancer mortality by inhibiting 
tumor angiogenesis, and treating vascular diseases by promoting angiogenesis.   
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CHAPTER 2 
LITERATURE REVIEW 
2.1 The VEGF Family 
The vascular endothelial growth factor-A (VEGF-A) is a key growth factor that promotes 
angiogenesis. The existence of VEGF-A was first hypothesized as an unknown factor by Judah 
Folkman in 1971, who characterized VEGF-A as an unknown tumor-angiogenesis factor [16]. 
Senger et al identified this unknown factor as vascular permeability factor (VPF) in 1983 [48], 
and Leung et al characterized this factor, and termed it VEGF, in 1989 [49]. Keck et al showed 
in 1989 that VPF and VEGF are the same molecule [50], demonstrating that this single factor has 
multiple functions. In 1993, Napoleone Ferrara’s laboratory demonstrated for the first time that 
inhibiting VEGF suppresses tumor growth [51]. Since these studies, VEGF has been studied as a 
promising therapeutic target for cancer and vascular disease, reviewed in [15], [52]. Anti-
angiogenic therapeutic approaches that have been applied to inhibit tumor angiogenesis are 
reviewed in [53]. An overview of the VEGF-directed angiogenesis timeline is given in Figure 
2.1. 
VEGF-A is now known as one of five related growth factors expressed in humans that 
make up the VEGF family: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor 
(PlGF) [54]. There are two additional VEGF ligands: viral VEGF (VEGF-E) [55] and snake 
venom VEGF (VEGF-F) [56]; these ligands are not expressed in humans, and as such, shall not 
be discussed in detail here. The VEGF growth factors bind with high affinity to three tyrosine 
kinase receptors, VEGFR1, VEGFR2, and VEGFR3. Many VEGF ligands also contain a 
heparin-binding domain, in addition to binding neuropilins, co-receptors to the VEGFRs. VEGF-
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A, often referred to simply as VEGF, promotes angiogenesis through interaction with VEGFR1 
and VEGFR2. Conversely, all other VEGF growth factors and VEGFR3 exhibit weak angiogenic 
potential. VEGF-B and PlGF specifically bind VEGFR1, and have been identified as key 
promotors in neurogenesis and embryogenesis. VEGF-C and VEGF-D promote 
lymphangiogenesis through VEGFR3 (Table 2.1).  
The VEGF ligands and receptors are also expressed in isoform variants, each having 
specific interactions and functions. VEGF-A has seven currently known splice variants, in 
addition to full-length VEGF-A, which are distinguished by amino acid length: VEGF-A121, 
VEGF-A145, VEGF-A148, VEGF-A165, VEGF-A183, VEGF-A189, and VEGF-A206. A VEGF-A110 
isoform is also created through proteolytic cleavage of longer VEGF isoforms by plasmin [57]. 
VEGF-regulated angiogenesis research typically focuses on VEGF-A165, the predominant 
VEGF-A isoform [58]. For this reason, VEGF-A165 is often referred to simply as VEGF, a 
notation I adopt henceforth.  
The aforementioned splice variants have recently been typified as the VEGF-Axxxa 
isoforms, as secondary VEGF-Axxxb isoforms containing the same number of amino acids, but 
different sequences and function, have emerged. Currently, four VEGF-Axxxb isoforms have been 
identified: VEGF-A121b, VEGF-A145b, VEGF-A165b, and VEGF-A189b, fully reviewed in [59], 
[60]. Key points to know about these isoforms include: VEGF-A165b  is the best studied VEGF-
Axxxb isoform; VEGF-A165b binds to VEGFR2 with the same kinetics as VEGF-A165, but does not 
activate VEGFR2 nor the signaling pathways that VEGF-A165 activates [61]. Subsequently, the 
VEGF-Axxxa isoforms are characterized as pro-angiogenic, whereas the VEGF-Axxxb isoforms are 
anti-angiogenic.  
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Likewise, multiple isoforms of VEGF-B have also been discovered [62], [63]. VEGF-B 
is considered to primarily be a neuroprotective factor [64]; VEGF-B has also been identified to 
act as a myocardium-specific angiogenic factor [65], [66] and a regulator of energy metabolism 
by modulating fatty acid uptake [67], reviewed in [68], [69]. The two discovered VEGF-B 
isoforms are VEGF-B167 and VEGF-B186, differentiated by amino acid length [62], [63]. VEGF-
B167 has been identified as the predominant isoform, with over 80% total VEGF-B being 
expressed as VEGF-B167 [70]. However, the functional differences between VEGF-B167 and 
VEGF-B186, outside that VEGF-B167 contains a heparin-binding domain and VEGF-B186 does not 
[68], are currently unknown.  
Conversely, VEGF-C does not exist in multiple isoforms. VEGF-C is considered to 
primarily promote lymphangiogenesis through interaction with VEGFR3, reviewed in [71]. 
VEGF-C also interacts with VEGFR2, although VEGF-C/VEGFR2 interactions do not appear 
sufficient to promote lymphangiogenesis [72]. VEGFR2 might have an indirect modulatory role 
in VEGF-C lymphangiogenesis: VEGF-C induces VEGFR2/VEGFR3 heterodimerization, unlike 
VEGF-A, which differentiates VEGF-C signaling from VEGFR3 homodimers [73], [74].  
Similarly, VEGF-D does not exist in multiple isoforms, and is considered to primarily 
promote lymphangiogenesis through VEGFR3, as reviewed in [75]. VEGF-D also binds 
VEGFR2 [76], implying that VEGFR2/VEGFR3 heterodimerization might be important for 
VEGF-D signaling. However, unlike with VEGF-C, lymphatic development does not appear to 
be affected by VEGF-D deletion [77]. As such, VEGF-D signaling and function remains 
questionable, and additional research is necessary to make any additional assertions about 
VEGF-D signaling. 
7 
 
PlGF contains four known isoforms, termed PlGF1-4 [78]–[80]. Similar to VEGF, PlGF 
isoforms result from alternative splicing, each containing a different number of amino acids: 131, 
152, 203, and 224. Like the VEGF-B isoforms, PlGF-2 and PlGF-4 contain heparin binding 
domains, while PlGF-1 and PlGF-3 do not [81]. Also like the VEGF-B isoforms, the functional 
difference between PlGF isoforms is not currently known.  
Similar to the VEGF ligands, the VEGFRs are also expressed in variant isoforms. Soluble 
isoforms, truncated full-length receptors without the transmembrane or intracellular domains, 
were identified for all three VEGFRs [82]–[84]. These soluble isoforms are considered to contain 
no signaling properties, acting to sequester free VEGF [83], [85]. The soluble VEGFR isoforms 
can dimerize with full-length membrane VEGFRs, which may additionally direct VEGFR 
signaling [86]. Intracellular VEGFR isoforms also exist; intracellular VEGFR1 isoforms 
containing either the full or partial intracellular domain of full-length VEGFR1 were identified 
[87], [88]. It stands to reason that other VEGFR isoforms may yet be undiscovered. Identifying 
all VEGFR isoforms and functions may be necessary to achieve complete control of 
angiogenesis. 
Dimerization, the binding of two receptor monomers to form a receptor dimer, is a 
critical step to VEGFR phosphorylation and signal transduction. VEGFR1, VEGFR2, and 
VEGFR3 all form homodimers: two VEGFR1 monomers bind to form a VEGFR1-VEGFR1 
homodimer, etc. Heterodimerization, where two different VEGFR monomers bind, also occurs. 
VEGFR2 forms heterodimers with both VEGFR1 and VEGFR3, whereas VEGFR1 and 
VEGFR3 are not able to heterodimerize. These homodimer and heterodimer pairs can activate 
different intracellular signaling pathways, leading to differential cell responses.  
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Overall, this VEGF family overview showcases the large VEGF signaling network. The 
multiple ligand types, receptor types, isoforms, and dimers complicate the ability to understand 
and predict how angiogenesis occurs. Furthermore, VEGF signaling cooperates with signaling 
from other receptors to direct angiogenesis: VEGF-VEGFR and Delta-Notch signaling interact to 
direct tip/stalk cell selection in sprouting angiogenesis, reviewed in [89]. Thus, the ability to 
effectively regulate angiogenesis for cancer and vascular disease therapeutics has relied on 
methods that delineate this complex VEGF signaling axis to identify key signaling features and 
targets. 
Here, I discuss how systems biology has been used to provide this delineation of VEGF 
signaling, to identify key VEGF signaling features and targets, in angiogenesis. Systems biology 
is an iterative approach between mathematical or computational modeling with quantitative 
experimentation to understand the entire biological system [90]. Systems biology is also 
advantageous by being quantitative and predictive in nature, allowing features such as model-
directed experiments to quicken discovery of key angiogenesis nodes. Systems biology also has 
the power to isolate and examine subsystems within angiogenesis, such as receptor signaling 
pathways to identify critical signaling nodes in angiogenesis. As such, systems biology can 
examine a system at various scales: angiogenesis can be examined macroscopically, such as 
sprout formation, or microscopically, such as VEGFR signal propagation.  
In this chapter, I provide an overview of systems biology techniques that have been 
employed to mathematically or computationally explore angiogenesis (Table 2.2). I review 
studies employing these systems biology techniques to examine the VEGF family in 
angiogenesis to provide new biological insights, and to design pro-angiogenic or anti-angiogenic 
therapies. Lastly, I provide a brief overview on the current challenges in manipulating VEGF 
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signaling and angiogenesis and future research directions to achieve complete angiogenic 
control.  
2.2 Systems Biology Approaches 
2.2.1 Deterministic kinetic modeling.  
Chemical reactions describing the kinetic reaction network are modeled using the law of 
mass-action: the rate of a reaction is directly proportional to reactant concentration (1.1): 
[[ ] [ ] ]A B C
f
r
k
k
            (1.1) 
Here A, B, and C are species concentrations, A and B interact to form C with forward 
rate kf, and C dissociates to form A and B with reverse rate kr. For systems biology applications, 
reactions describe interactions between reactants, modeled as biological species such as proteins 
or genes. For deterministic kinetic models, species are assumed to be contained in a continuous 
molecular concentration. One typical deterministic kinetic modeling application is to quantify 
temporal species concentrations using ordinary differential equations (1.2): 
[ ]
[ ] [ ][ ]r f
d A
k C k A B
dt
                        (1. 2) 
The equation in (1.2) indicates the temporal concentration of species A ([A]) defined by 
the chemical reaction in (1.1). Kinetic models are also often employed as compartmental models, 
where species reactions are bounded within a physical space (compartment), but may transport 
between other compartments that are physically separated (Fig 2.2). In systems biology, a 
microscale compartmental example is modeling the extracellular and intracellular space, which 
are physically separated by the cell membrane. A macroscale example is modeling compartments 
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as different tissues, such as bloodstream and skeletal muscle tissue, which are physically 
separated by the blood vessel walls. A thorough review on kinetic modeling of signaling 
networks at micro- and macro-scales can be found by Janes and Lauffenburger in [91]. 
A second typical deterministic kinetic modeling application is to quantify spatial or 
spatiotemporal species concentrations are using the advection-diffusion-reaction equation 
modeled with partial differential equations (1.3): 
[ ] R
[ ]
[ ]2 v A
A
D A
t
 

  

           (1.3) 
where [A] is the concentration of a species A, D is the diffusion coefficient of species A,   is 
the spatial gradient, v  is the convective velocity field, and R is any reactions involving species 
A. In purely kinetic models, modeling species diffusion and convection typically involves 
compartmental modeling, where species transport between compartments is defined by either 
constant D and v  terms, or D and v  terms that are altered algorithmically (Fig 1.1).    
2.2.2 Stochastic modeling 
Deterministic kinetic modeling always gives the same results given the same reactions, 
concentrations, and kinetics. However, biological processes have elements of randomness; 
deterministic modeling particularly fails at low species concentrations, where the assumption that 
species are contained in a continuous molecular concentration does not hold, and reactions occur 
stochastically [92], [93]. Stochastic kinetic models incorporate this random element into 
deterministic kinetic models to predict biological randomness and noise [94]. Systems biology 
typically applies stochastic modeling through the Gillespie algorithm or Monte Carlo 
simulations. Briefly, the Gillespie algorithm simulates time-dependent trajectories of the species 
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in a chemical reaction network [94]. Monte Carlo simulates stochastic reactions by introducing 
probability distributions for the occurrence of each reaction [95].  
2.2.3 Agent-based modeling 
Agent-based models represent each individual species (i.e. cell or protein) as a discrete 
agent that follows a certain set of rules. Similar to kinetic modeling, agent-based models in 
systems biology are typically used to quantify spatiotemporal species information [96]. Unlike 
kinetic modeling, agent-based models do not require kinetic or concentration information; rather, 
rules define species interactions and transport, which may or may not include kinetic or 
concentration information [90]. Cellular automaton is one primary example of agent-based 
modeling: creating a two- or three-dimensional spatial grid, where each lattice on the grid 
contains an agent of interest, and simulating the spatiotemporal agent movements and 
interactions across the grid. 
Agent-based models are advantageous as they incorporate stochasticity, and provide 
spatiotemporal information on individual agents, without requiring complex mathematical 
equations (such as 1.2-1.3) to be defined and solved. Furthermore, agent-based models do not 
require knowledge of the system mechanisms; agent behavior is governed by rules that can be 
readily derived from physical laws or empirical observations. One primary limitation of agent-
based models is that simulating many agents is highly expensive computationally [97]. Thus, 
agent-based models are useful for testing multiple system mechanisms to uncover the true 
system behavior [96].  
2.2.4 Molecular modeling 
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Molecular modeling simulates the three-dimensional structural interactions between 
atoms and molecules [98]. Here, I focus on molecular modeling in the context of computational 
drug screening to identifying potential VEGF inhibitors [99]. Computational drug screening is an 
approach to identify novel therapeutics for targeting signaling proteins. Potential drugs targeting 
the signal protein of interest are predicted by screening through different molecules, and 
quantifying their binding strength to the signal protein. Binding strength is typically determined 
through docking analysis, predicting the ability of a molecule to bind the signal protein through 
preferred orientation, size, flexibility, predicted interaction kinetics, and atomic structure. The 
therapeutic efficacy of these drugs is then examined in vitro or in vivo [99].  
2.2.5 Finite element modeling 
Finite element modeling is based on similar principles of cellular automaton: a spatial 
domain is bounded and discretized to calculate the quantity of interest within each lattice on the 
grid temporally [100]. Finite element modeling differs from agent-based modeling in two 
primary ways: (1) finite element models quantify materials in continuum, such as fluid velocities 
or temperature fields, and (2) finite element models are defined from conservation laws. A 
typical finite element application is to quantify hemodynamic forces, velocity, pressure, and 
shear stresses, through the Navier-Stokes equations [101]: 
, ( )t p     uu u u u f                        (1.4) 
0 u                     (1.5) 
where   is the fluid density, u  is the velocity field, ,tu  is the time derivative of the velocity 
field, u  is the viscous stress, p  is the pressure, and f  is the external forces. The equations in 
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(1.4) and (1.5) are defined by conservation of momentum and mass respectively. Finite element 
models could be used to calculate physiologically relevant velocity fields for advection-
diffusion-reaction simulations (1.3), allowing multi-scale VEGF modeling. For angiogenesis 
applications, finite element modeling is typically used to examine how blood flow stress directs 
vessel growth or intravenous angiogenic drug delivery. 
2.2.6 Multivariate models 
The above computational techniques require no experimental data training for model 
development – granted such models are typically trained to ensure physiological accuracy. 
However, these models require high parameterization when the number of reactions and species 
becomes large, and not all species or variables related to the system are typically incorporated 
into these models. To overcome these challenges, multivariate models seek to provide signal-to-
response statistical models derived directly from experimental datasets, which do not require 
explicit definition of system mechanisms. A commonly used multivariate model in systems 
biology is partial least squares regression (PLSR). PLSR is a regression technique that correlates 
independent variables to dependent variables within the system [102]. An example is building a 
PLSR model to correlate ligand stimuli (independent variable) to cell response (dependent 
variable) using experimental observations, and then applying the PLSR model to predict what 
cell responses will occur from untested ligand stimuli [102].  
Statistical modeling is another commonly used multivariate approach in systems biology, 
where the probability of observing some response from a system of interest is calculated given a 
probability model [103]. Bayesian statistics is one such commonly used statistical model; 
Bayesian statistics infers posterior probabilities of model parameters by model training with 
empirical data [104]. An example Bayesian model application is predicting receptor signaling 
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cross-talk involved in drug resistance, using empirical gene expression profiles from drug-
resistance and drug-nonresistant patients [105]. Machine learning is a similar statistical modeling 
approach, which describes a system from empirically derived sample inputs through processing 
algorithms [106]. Machine learning differs from Bayesian statistics in that machine learning does 
not describe biological mechanisms of a system, rather providing an optimized fit of input data to 
response. An example machine learning application is mapping tissue gene expressions to 
disease groups, to allow predictive disease classification from future tissue gene expression 
screenings [107].    
While multivariate models are powerful at predicting signal-to-responses, they are 
empirical-based models that are not capable of describing mechanisms of a biological system. 
Since this literature review focuses on computational systems biology for understanding 
angiogenesis mechanisms, I do not review multivariate approaches for angiogenesis in detail.  
In the following section, I provide an overview of computational systems biology studies 
that explore angiogenesis mechanisms and methods for regulating angiogenesis.   
2.3 Systems Biology for Studying Angiogenesis 
2.3.1 Sprouting angiogenesis 
Computational modeling, as a tool to understand angiogenesis, has been applied hand-in-
hand with experimental investigation since the field of angiogenesis first emerged in the early 
1970s, when Judah Folkman discovered the tumor angiogenic factor [16]. The earliest 
angiogenesis computational models examined vessel sprouting and network formation by 
diffusion modeling [108], [109]. As VEGF and VEGFRs were not characterized until the late-
1980s to early 1990s (Fig 2.1), these initial angiogenesis models examined vessel sprouting in 
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response to the uncharacterized molecule tumor angiogenic factor [16]. Despite not modeling 
sprouting directly by VEGF, these early computational models offered many important insights 
into growth factor directed angiogenesis. Such computational models determined that the 
presence of an angiogenic factor is necessary to develop high density tumor vascularization, a 
concept that was contentious for its time [108], [110]. Later sprouting models highlighted the 
importance of an angiogenic factor, finding that directed vessel growth [111] and vessel loop 
formation [112] require a growth factor gradient. Cellular automaton and random walk 
approaches were applied to track individual cells throughout sprouting [113], which captured the 
proliferative phenotype of cells behind the sprouting tip [114].  
As the roles of VEGF and other factors became defined in angiogenesis, computational 
models began to examine sprouting as a system comprising multiple driving factors or cell types. 
Some such recent sprouting models have predicted that basic fibroblast growth factor (bFGF) 
enhances VEGF-directed angiogenesis by upregulating VEGFR2 [115], and that VEGF and 
angiopoietins coordinate angiogenesis through endothelial cell (EC) migration and vessel 
maturation by pericytes [116]. Finite element modeling has also been used to identify that 
traction forces employed by cell growth controls matrix deformation and additional angiogenic 
growth and remodeling [117]. Additional computational systems biology models that have been 
specifically studied sprouting angiogenesis are reviewed in [118]. Overall, such sprouting 
models have advanced the understanding of how single or multiple growth factor gradients direct 
angiogenesis. Sprouting models also offer a powerful, macroscopic framework to examine 
specific subsystems within angiogenesis; as such, sprouting models have been extended to 
understand how VEGF-mediated tip/stalk cell selection directs angiogenesis. 
2.3.2 Tip/stalk cell selection and vessel sprouting 
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Gerhardt et al defined vessel patterning for the first time in 2003, characterized by tip 
cells responding to VEGF with guided migration, and stalk cells responding with proliferation 
[119]. Vessel patterning has since been well characterized in VEGF-directed sprouting 
angiogenesis, identified as an important feature for VEGF signaling and lumen formation to 
create functional blood vessels, reviewed in [120]. As VEGF/VEGFR and Delta/Notch signaling 
cross-talk was characterized as a key feature in tip/stalk cell selection and vessel patterning 
[121], [122], agent-based computational models worked hand-in-hand with experimental 
investigations to explore this relationship. Insights gained from such agent-based models include 
identifying that Dll4 and VEGFR2 expression oscillate to direct sprouting [123], and the 
validated prediction that tip/stalk cell selection is driven through tip cell filopodia extension 
[124]. Perhaps the most important insight into tip/stalk cell selection given by computational 
models is that this process is reversible; Bentley et. al. first reported that DII4/Notch lateral 
inhibition between ECs during loop formation causes cell fates to flip [124], a process now 
validated through further model-directed [125] and exploratory [126] experiments. Recent agent-
based modeling, integrated with in vivo experiments, identified that the rate of tip cell selection 
defines a trade-off between sprout extension and vessel branching, dictating vessel network 
density [127]. Model-derived experiments also found that reversible tip/stalk cell selection is 
present in embryonic neural crest cells, accurately predicting gene expression patterns that 
different tip and stalk cells [128], [129]. Some examples of inferences recent tip/stalk cell 
sprouting models have made include: tip cells migrate back and forth to dynamically alter the 
leading cell based on VEGFR2 expression [130], stalk cell proliferation is dependent on traction 
forces applied by tip cell migration [131], and that tip cell polarization and directed movement is 
mediated by the VEGF-VEGFR binding distribution on the cell surface [132].  
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2.3.3 VEGF-VEGFR kinetic models 
VEGF-VEGFR kinetic models at the single cell scale seek to understand how the kinetics 
of the ligand-receptor interactions dynamically alter protein and complex concentrations. 
Typically, these concentrations are taken as the functional output of VEGF-VEGFR interaction 
models, providing inference to angiogenic potential (i.e. higher phospho-VEGFR2 
concentrations imply more angiogenesis will occur). VEGF-VEGFR interaction models are 
powerful as they quantify protein and complex concentrations that are difficult to probe or 
differentiate experimentally, and allow perturbations (such as ligand or receptor concertation 
effects) to be easily examined. While ligand-receptor kinetic models were first introduced in the 
early-1970s  [133], VEGF-VEGFR interactions would not be explored until Mac Gabhann and 
Popel developed the first VEGF-VEGFR kinetic model in 2004 [134]. This model predicted that 
the experimental hypothesis that PlGF displaces VEGF from VEGFR1, enhancing VEGF 
signaling through VEGFR2, was incorrect, and suggested a functional VEGFR1 signaling role 
[134]. Later experimental evidence backed up this model result, showing that PlGF upregulates 
pro-angiogenic factors and induces metastasis [135], [136]. This initial model showcases the 
predictive power of VEGF-VEGFR interaction models. VEGF-VEGFR interaction models have 
been continuously developed throughout the years to explore VEGFR signaling dynamics. I 
provide an overview of VEGF-VEGFR kinetic models based on the subsystems they explore. 
2.3.4 VEGF expression in hypoxia 
Hypoxia inducible factor-1α (HIF-1α) is one of the primary molecules that directs 
vascularization in response to hypoxic environments by promoting VEGF expression [137], 
[138], leading to increased tumor cell invasiveness [139].  Systems biology has thus investigated 
HIF-1α activation in response to oxygen concentration, and subsequent VEGF expression for 
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promoting angiogenesis. An initial hypoxia kinetic model developed by Qutub and Popel 
identified that HIF-1α activation from hypoxia either directs steep, switch-like or gradual cell 
responses; this dual cell response may be an important consideration for HIF-1α targeting 
therapeutics [140]. Another kinetic model examined how VEGF expression is mediated through 
HIF-1α degradation by two enzymes, prolyl hydroxylase and asparaginyl hydroxylase [141]. 
This model identified that prolyl hydroxylase alone is sufficient at abolishing HIF-1α activity, 
and that regulating prolyl hydroxylase activity may be an effective method for controlling the 
angiogenesis response to hypoxia [141]. A recent kinetic model examined the role of miRNAs in 
hypoxia-induced HIF-1α activity and VEGF expression, identifying that argonaute 1 
overexpression decreases VEGF production [142]. These potential therapeutic targets identified 
by hypoxia-induced VEGF expression models offer potential options for controlling 
angiogenesis, and require further investigation.   
2.3.5 VEGFR dimerization models 
VEGF signaling can lead to differential signaling outcomes based on whether it signals 
through VEGFR homodimers or heterodimers [143]. VEGFR dimerization formation is difficult 
to examine experimentally, making the effects of dimerization parameters, such as dimerization 
rates or ratio of dimer formation, difficult to elucidate. VEGF computational models have 
provided VEGFR dimerization to be probed, with such findings as that dimerization does not 
affect complex formation at membrane patches dominated by stochastic VEGF-VEGFR binding 
[144]. Modeling competition of VEGF-VEGFR complex formation between VEGFR 
homodimers and VEGFR1/VEGFR2 heterodimers revealed that 10% - 50% complexes exist as 
heterodimers [145]. Furthermore, when VEGFR2 concentrations are high, heterodimer formation 
increases by decreasing VEGFR1 homodimer formation [145], a prediction validated 
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experimentally [146]. While these computational models elucidated how VEGFR dimers form, 
understanding functional differences in VEGF signaling through VEGFR1 homodimers, 
VEGFR2 homodimers, and VEGFR1/VEGFR2 heterodimers remains a challenge that systems 
biology may yet answer. 
2.3.6 VEGF isoform-VEGFR kinetic modeling 
Similar to VEGF signaling being directed by VEGFR dimer formation, VEGFR signaling 
is directed by the type of ligand that binds (Table 2.1). While computational models have 
examined VEGF isoforms primarily in the context of pathology (described below), I highlight 
three studies that have examined VEGF isoforms in normal physiology. An early model 
examining VEGF165- and VEGF121-VEGFR binding distributions in skeletal muscle tissue found 
that NRP potentiates VEGF165-VEGFR2 binding, and removing NRP causes equal VEGF165- and 
VEGF121-VEGFR2 binding [147]. A two compartment blood-tissue model examined VEGF121 
and VEGF165 binding distributions with luminal and abluminal receptors, finding that abluminal 
VEGF predominantly binds VEGFR1, whereas luminal VEGF predominately binds VEGFR2 
[148]. Another study elucidated that VEGF isoform patterning observed in vivo [149], [150] is 
directed by isoform specific sequestration and degradation through heparan sulfate proteoglycan 
binding [151]. Furthermore, matrix metalloproteinases increase soluble VEGF by cleaving 
heparan sulfate proteoglycans and preventing VEGF degradation [151], [152]. Note that these 
computational models examined VEGF121, VEGF165, and VEGF189 binding distributions with 
VEGFRs; no other VEGFxxxa isoforms have been modeled, and no VEGFxxxb isoform models 
exist to the best of my knowledge.   
2.3.7 Kinetic modeling of VEGFR internalization and intracellular signaling 
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These extracellular models provide a template for identifying key extracellular nodes and 
processes mediating VEGF-VEGFR interactions, but do not characterize how intracellular nodes 
mediate angiogenesis. To overcome this limitation, VEGF computational models were extended 
to examine how extracellular factors and VEGF-VEGFR binding couple with intracellular 
processes, receptor internalization and intracellular signaling, to direct angiogenesis. These 
VEGFR signaling models have focused on VEGFR2, whose intracellular signaling role in 
angiogenesis has been well characterized experimentally, relative to VEGFR1 [153], [154]. The 
earliest VEGFR intracellular signaling model I identified, developed in 2007 by Alarcon and 
Page, provides the mathematical basis for modeling VEGF binding a generalized VEGFR, 
VEGFR internalization, and coupling of a generalized src-homology 2 (SH2) containing kinase 
to the VEGFR [155]. Such mathematical techniques have been applied to examine specific 
signaling molecules: Mi et al use model-directed experimentation to show that VEGFR2-PLCδ 
directs intercellular Ca
2+
 signaling, mediating cell-cell communication in wound closure [156]. 
Napione et al show through model and experimentation that PLCγ and Akt phosphorylation 
depend on VEGFR2 expression, mediated by cell density [157]. Tan et al predict that VEGFR2 
activates multiple different pathways, mediated by Gab1 and Gab2, to control Akt 
phosphorylation dynamics [158]. Computational analyses have also identified an important role 
for receptor internalization in intracellular signaling; matrix-bound VEGF is predicted to be 
internalized slowly by VEGFR2, facilitating higher and sustained ERK phosphorylation, relative 
to soluble VEGF [159]. Similarly, Anderson et al experimentally show that heparin-bound 
VEGF increases VEGFR2 phosphorylation, and through computational modeling identify that 
heparin-bound VEGF slows receptor internalization [160]. Another model predicts that receptor 
phosphorylation is more dependent on internalization and trafficking rates than phosphorylation 
21 
 
rates, indicating that phosphorylation of specific receptor sites may depend on intracellular 
compartmentalization [161]. Together, these VEGF-VEGFR interaction models provide systemic 
information on the VEGF signaling axis: mapping entire extracellular and intracellular processes 
that mediate VEGF signaling and subsequent angiogenesis.  
2.3.8 Multiscale VEGF kinetic models  
VEGF interaction models have been expanded from the cell surface to macroscale. These 
systemic VEGF computational studies model the same VEGF-VEGFR interactions as at the cell 
scale, but expand the model scope to and interactions to examine VEGF distribution and binding 
at tissue or whole-body scales. At the tissue scale, VEGF165 and VEGF121 binding distributions to 
VEGFRs and NRP1 were modeled in skeletal muscle tissue, providing tissue scale findings such 
as that VEGF165 concentrations in interstitial space does not affect steady-state VEGF binding 
distributions [147]. VEGF interactions are also modeled at the whole-body scale, using 
compartmental modeling to simultaneously quantify VEGF interactions and transport between 
biological compartments. Whole-body VEGF models first emerged by examining VEGF in 
tissue and blood compartments [162], providing the notable insights that unbound VEGF 
primarily localizes to tissue compartments [163], and but that soluble VEGFR1, which 
sequesters unbound VEGF, does not decrease VEGF signaling potential in those tissue 
compartments [164]. These macroscopic VEGF-VEGFR interaction models are also regularly 
used to explore angiogenesis in pathology: understanding both how VEGF signaling is important 
to pathology, and testing VEGF therapeutics. In the following section, I review modeling 
approaches to explore and optimize VEGF therapeutics, specifically pro-angiogenic therapeutics 
for vascular disease, and anti-angiogenic therapeutics for cancer. 
2.3.9 Systems biology for pro-angiogenic therapies 
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Pro-angiogenic treatments have exhibited continuous success at vascularizing ischemic 
tissue in animal models, but such treatments have not translated to clinical benefits [165]. 
Computational models for pro-angiogenic therapies seek to optimize VEGF signaling to 
vascularize ischemic tissue and provide clinically effective options for treating vascular diseases 
[166]. Pro-angiogenic computational models first examined VEGF gradients in rest and exercise 
[167], [168], as exercise is the most effective preventer of vascular disease [169]. Some key 
findings from these computational studies include (1) that skeletal muscle VEGF gradients result 
in heterogeneous VEGFR activation, which may define the mechanism for stochastic sprout 
locations [168], (2) exercise increases VEGF signaling by upregulating VEGFRs and NRP1 
[167], and (3) VEGF signaling and subsequent tissue vascularization is most effective within the 
first week of starting exercise regimes [167]. Unfortunately, patients with progressed vascular 
disease are unable to exercise; thus, computational models also examined other pro-angiogenic 
therapies in severe artery diseases [142], [170], [171]. One model suggested that injecting 
myoblasts overexpressing VEGF may effectively promote angiogenesis [171], and although 
further study identified this treatment to be less effective than exercise [170], it may be a 
promising therapeutic for patients unable to exercise. A recent model suggests that targeting 
miRNA, specifically inhibiting miR-15a, may effectively increasing VEGF synthesis and 
function in peripheral artery disease [142]. Further exploration into miR-15a in peripheral artery 
disease, along with additional computationally derived therapeutic options for vascular diseases, 
may overcome the barrier currently preventing clinical efficacy of pro-angiogenic therapies.  
2.3.10 Systems biology for anti-angiogenic therapies 
Whole-body pharmacokinetic/pharmacodynamics VEGF interaction models have been 
developed to systemically quantify VEGF-targeting therapeutic efficacies to inhibit tumor 
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angiogenesis. These tumor angiogenesis models extend compartmental models of VEGF 
interactions with VEGFRs and extracellular proteins [148], [164], [172] to account for drug 
administration to the blood stream, absorption into healthy and diseased tissue, and drug-target 
interactions. Compartmental models examined VEGF dynamics following anti-VEGF injection 
[173]–[175], identifying that VEGF121 inhibition is more effective at reducing tumor angiogenic 
potential than VEGF165 inhibition [176] and predicted that anti-VEGF efficacy is sensitive to 
VEGFR levels on tumor cells [177]. Further investigation into physiological VEGFR 
heterogeneity identified that high VEGFR1 levels result in ineffective anti-VEGF therapy [178], 
implicating VEGFR heterogeneity as a drug resistance mechanism. Pharmacokinetic modeling 
has also identified potential drug interaction mechanisms: the anti-VEGF drug aflibercept may 
bind NRP-bound VEGF, in addition to free VEGF [179]. Overall, these systemic VEGF models 
offer a powerful platform for testing anti-tumor angiogenesis therapies, which can be applied to 
study patient-specific therapeutic efficacy, in addition to elucidating mechanisms of drug 
interactions and resistance. 
2.3.11 Computational drug screening for VEGF-therapeutics 
Computational drug screening has recently been applied to identify possible molecular 
compounds that selectively inhibit VEGFR2. These screening approaches typically iterate 
through compounds available in molecular databases, and identify potential novel VEGFR2-
inhibitors through a computational structural comparison to an established VEGFR2 inhibitor 
[180]. The compounds exhibiting the greatest therapeutic potential are then tested 
experimentally. Such structural screening studies have identified a compound, termed HP-14, 
that exhibits a four-fold higher reduction in HUVEC proliferation than the established VEGFR 
inhibitor Vatalanib [181], [182]. Other screening studies have identified compounds that 
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significantly inhibit VEGFR1 and VEGFR2 phosphorylation to prevent HUVEC tube formation 
in vitro [183], inhibit VEGFR2 kinase activity and HUVEC wound closure without affecting 
HUVEC proliferation [184], and inhibit vessel sprouting ex vivo [185]. Further review of anti-
angiogenic VEGFR2-targeting therapies identified through computational screening can be 
found in [186]. This computational screening approach, linked with experimental validation, 
offers rapid identification of promising VEGF inhibitors that may allow optimizing patient-
specific therapeutics.  
2.4 Current Challenges in Angiogenesis Research 
2.4.1 Overcoming resistance of VEGF-targeting therapeutics. 
Overall, computational studies and systems biology have driven angiogenic research 
fundamentally and to direct angiogenic therapeutics. Many challenges remain to be overcome to 
obtain complete control of angiogenesis. Overcoming anti-VEGF drug resistances is a large 
challenge in providing effective cancer treatment by inhibiting angiogenesis [187]–[189]. Such 
therapeutic resistance was connected with heterogeneity in endothelial cell protein profiles [190], 
leading to systems biology studies that provided mechanistic insight into anti-VEGF resistance: 
high VEGFR1 cell subpopulations result in ineffective anti-VEGF treatment [178], a result 
observed clinically [191]–[193]. Despite such advances, anti-VEGF and other VEGF targeting 
therapeutics are still met with resistance in many patients [194]. A complete, systematic and 
quantitative understanding of VEGF signaling is necessary to overcome VEGF-targeted drug 
resistance and deliver personalized treatment regimes. 
2.4.2 Quantifying VEGFR signaling throughout endocytosis.  
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One primary challenge in achieving complete angiogenic control is to understand the 
relationship between endocytosis and VEGFR signaling. Recently, intracellular-based receptors 
have emerged as key signal transducers [195], [196], yet signaling from intracellular VEGFRs 
remains undefined. While recent computational models have examined intracellular-based 
VEGFR2 phosphorylation [161] and kinase phosphorylation [158], [159], only the VEGFR 
recycling pathway was modeled; no known computational models account for VEGFR nuclear 
translocation or modulation of gene expression via intracellular VEGFRs. Furthermore, the high 
intracellular expression of VEGFR1 and VEGFR2 [197] indicates that intracellular VEGFRs 
endocytosis may have a crucial role in mediating VEGFR signaling. 
2.4.3 Mapping the VEGF isoform functions.  
Another primary challenge in controlling angiogenesis is elucidating the function of all 
VEGF proteins. Specific functions for most VEGF isoforms remain undefined. While systems 
biology has identified differential VEGF165 and VEGF121-VEGFR binding and function, few of 
the other VEGF isoforms have been studied computationally or experimentally. VEGFxxxb 
functions in particular remain undefined, but may be important for angiogenesis; a recent study 
identifying that VEGF165b alters Dll4 expression [198], together with evidence that targeting 
Delta-Notch signaling may be effective anti-cancer therapeutic [199], implies an important 
VEGFxxxb role for tumor angiogenesis. Additionally, VEGFxxxb may have higher expression than 
VEGFxxxa in certain diseases [200], further highlighting the necessity to understand VEGFxxxb 
functions. Unlocking the mechanisms that mediate VEGF isoform expression, binding, and 
signaling may be the key to overcoming VEGF therapeutic resistance. 
2.4.4 Uncovering the VEGFR1 signaling role.  
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Similarly, the VEGFR1 signaling function remains poorly defined, and there are 
currently no known intracellular signaling molecules that have examined VEGFR1 signaling 
specifically. Computational studies have generally ignored VEGFR1-based signaling due to the 
its classically defined decoy status in angiogenesis; VEGFR1 is thought to exhibit no 
intracellular signaling, serving to bind VEGF with high affinity to module VEGF binding and 
signaling through VEGFR2. However, emerging evidence implies an active VEGFR1 signaling 
role in angiogenesis: membrane VEGFR1 is upregulated during vascular reperfusion stages in 
ischemic tissue [201], hypoxic tumor cells, and tumor endothelial cells [202], and VEGFR1 
tyrosine kinase-deficient mice exhibit reduced angiogenesis [203]. Furthermore, PlGF stimulates 
endothelial cell growth and migration [204], [205], and inhibiting PlGF prevents tumor growth 
and metastasis [206]. Computational models identifying receptor post-translational modifications 
are able to determine receptor signaling pathways and function [207], [208]; therefore, 
computational models exploring VEGFR1 post-translational modifications can identify first 
whether VEGFR1 actively signals, and if so, map the VEGFR1 signaling pathways and 
VEGFR1-induced cell responses.    
2.4.5 VEGF signaling models for clinical applications.  
Towards using systems biology to guide angiogenic therapeutics, developing clinically 
relevant models that allow patient-specific investigation are essential [209], [210]. Developing 
such personalized models is a nontrivial task [211], necessitating multiscale modeling 
approaches to capture all clinical features relevant to angiogenesis, such as VEGF interactions at 
the microscale and hemodynamics at the macroscale [212], [213]. Integrating macroscale blood 
flow stress with microscale VEGFR signaling may be an important clinical consideration; shear 
stress induces VEGFR signaling [214], directs vessel patterning [215], and vessel sprouting may 
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be dependent on fluid flow-directed VEGF gradients [216]. Choosing which modeling approach 
to use also must be balanced between computational complexity and physiological accuracy; 
take hemodynamic modeling as an example: while modeling blood properties as Newtonian is 
less mathematically complex than modeling the shear thinning properties of blood, Newtonian 
models do not provide physiologically relevant hemodynamics [101]. Comprehensive 
angiogenesis computational models that guide therapeutic development for clinicians in an 
accessible, clinically relevant way is a large challenge in systems biology today, but would 
provide a platform for effective personalized medicine that no other approach can. 
2.5 Dissertation Research Overview 
 To address the challenge of overcoming drug resistance in anti-angiogenic cancer 
therapeutics, I developed a whole-body model quantifying how VEGFR heterogeneity directs 
bevacizumab (anti-VEGF) efficacy [178]. I also developed a benchmark platform for quantifying 
hemodynamics [101], as a first step to overcoming the challenge of modeling microscale VEGF 
kinetics with macroscale hemodynamics for physiologically and clinically relevant models. 
VEGFR heterogeneity was experimentally measured and converted to quantitative parameters 
for computational modeling using an approach I helped develop with my lab collaborators [217]. 
From this VEGFR heterogeneity study, I identified that high VEGFR1 levels, present on tumor 
associated endothelial cell subpopulations, result in ineffective anti-VEGF treatment [178], a 
result also found in clinical trials [191]–[193]. This effect did not occur from physiological 
VEGFR2 levels. From this model, I identified the anti-VEGF resistance mechanism in patients 
with high VEGFR1: VEGFR1 acts as a pool to protect VEGF from anti-VEGF.  
Particularly, this resistance mechanism can be broken into three stages: (i) before anti-
VEGF administration, (ii) short-term effects of anti-VEGF treatment, and (iii) long-term effects 
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of anti-VEGF treatment (Fig 2.3). (i) Before anti-VEGF is administered, high VEGFR1 
subpopulations reach an equilibrium state exhibited by a high VEGF concentration bound at the 
cell membrane and low free VEGF concentration extracellularly. Conversely, low VEGFR1 
subpopulations exhibit a low VEGF concentration bound at the cell membrane and high 
extracellular VEGF concentration at equilibrium. (ii) At short time points after anti-VEGF 
treatment, both high and low VEGFR1 subpopulations exhibit nearly complete sequestration of 
free VEGF, which is then rapidly cleared from the body. This results in a concentration gradient 
of high VEGF at the cell membrane and low extracellular VEGF, causing VEGF to unbind from 
the cell surface and diffuse into the extracellular space. (iii) Due to this VEGF diffusion away 
from the cell surface, high VEGFR1 subpopulations result in an increased free VEGF 
concentration following anti-VEGF treatment; low VEGFR1 subpopulations conversely result in 
a decreased free VEGF concentration (Fig 2.3).   
 The anti-VEGF resistance exhibited by high VEGFR1 subpopulations is characterized by 
two additional physiological phenomena: high VEGF-VEGFR1 binding and high VEGF-
VEGFR1 internalization (Fig 2.3). This first physiological phenomena, high VEGF-VEGFR1 
binding, implies these subpopulations purposefully express high VEGFR1 levels to produce high 
VEGFR1 signaling. However, the VEGFR1 signaling role and pathways has not been previously 
defined. Chapter 3 discusses my research to understand the VEGFR1 signaling role, showing 
that VEGFR1 actively signals to promote cell migration and proliferation through PLCγ and 
PI3K pathways. This second physiological phenomena, high VEGF-VEGFR1 internalization, 
implies that endocytosis is an important VEGFR1 signaling regulator. However, how 
endocytosis quantitatively regulates receptor signaling is not defined. Chapter 4 discusses my 
research to quantify the relationship between endocytosis and receptor signaling, showing that 
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receptor signaling primarily occurs intracellularly from endocytic vesicles, late endosomes, and 
the nucleus. Within these chapters, I also discuss the implications of my results to the larger 
fields of angiogenesis, systems biology, and therapeutics. 
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2.6 Figures and Tables 
 
Figure 2.1: Timeline of VEGF-directed angiogenesis research.  
Timeline highlighting the major discoveries and emergence of computational models in VEGF-directed 
angiogenesis. References refer to the discovery or the first known study to develop a computational model 
for that specific research area. 
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Figure 2.2: Example systems biology techniques to model protein transport and interactions.  
(A) A deterministic kinetic compartmental model containing a single chemical reaction involving two 
molecules [X] and [Y] binding to form [X:Y], all with units of M. The reaction is defined by the forward 
rate kf (M
-1
s
-1
) and reverse rate kr (s
-1
). In this example, X is a free molecule able to move across 
compartments, while Y is anchored within the compartment. Compartment 1 is blood that is spatially 
close enough to interact with tissue defined by Compartment 2, both with units of L. Blue arrows indicate 
diffusion, while the green arrow indicates convention from blood flow. For this kinetic model, diffusion 
and convection terms are assumed to have units of s
-1
. An example ordinary differential equation 
governing [X] in Compartment 1 is shown. (B) An agent-based model using a grid for spatial 
discretization. Pseudo-rules are given for directing agent motility and interactions. (C) Example of finite 
element modeling to determine blood flow velocities, taken from simulations performed in [101]. The 
blood velocity field can be integrated with kinetic or agent-based models to provide more physiologically 
relevant convection rates or movement probabilities, respectively. Conversely, the tissue could also be 
modeled with finite elements, and advection-diffusion-reaction could be solved. 
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Figure 2.3: Tumor endothelial cell subpopulations with high VEGFR1 levels result in ineffective 
anti-VEGF treatment. 
Tumor endothelial cell subpopulation responses to anti-VEGF treatment based on whether they express 
low (left) or high (right) VEGFR1 levels, derived from results found in [178]. High VEGFR1 
subpopulations are resistanct to anti-VEGF treatment, as free VEGF increases following anti-VEGF 
treatment. Low VEGFR1 subpopulations conversely are not resistance to anti-VEGF treatment, as they 
exhibit reduced free VEGF following anti-VEGF treatment. High VEGFR1 subpopulations are 
additionally characterized by high VEGF-VEGFR1 binding and high VEGF-VEGFR1 internalization. 
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Table 2.1: The VEGF family proteins.  
Protein Isoform Family Interactions  Primary Function Discovery 
VEGF-A  
 
 
 
 
VEGFR1, VEGFR2 
VEGF-A (homodimer) 
PlGF (heterodimer) 
 
 
Pro-angiogenic 
[48], [49] 
 VEGF-A110 [218] 
VEGF-A121 [219] 
VEGF-A145 [220] 
VEGF-A148 Unknown [221] 
VEGF-A165  
Pro-angiogenic 
 
[219] 
VEGF-A183 [222] 
VEGF-A189 [219] 
VEGF-A206 [223] 
VEGF-A121b  
Anti-angiogeneic 
 
[61] 
VEGF-A145b [224] 
VEGF-A165b [225] 
VEGF-A189b [61] 
VEGF-B VEGFR1 
VEGF-B (homodimer) 
Neurogenesis and 
embryogenesis 
[62] 
 VEGF-B167 [62] 
VEGF-B186 [63] 
VEGF-C VEGFR3, VEGFR2 
VEGF-C (homodimer) 
Lymphangiogenesis [226] 
VEGF-D VEGFR2, VEGFR3 
VEGF-D (homodimer) 
Lymphangiogenesis [76] 
PlGF  
VEGFR1 
PlGF (homodimer) 
VEGF-A (heterodimer) 
 
 
Pro-angiogenic 
[227] 
 PlGF-1 [78] 
PlGF-2 [78] 
PlGF-3 [79] 
PlGF-4 [80] 
VEGFR1 VEGF-A, VEGF-B, PlGF 
VEGFR1 (homodimer) 
VEGFR2 (heterodimer) 
Angiogenesis [228] 
 sVEGFR1 Anti-angiogenic [82] 
VEGFR2 VEGF-A 
VEGFR2 (homodimer) 
VEGFR1, VEGFR3 (heterodimer) 
Angiogenesis [229], 
[230] 
 sVEGFR2 Anti- angiogenic 
Anti-lymphangiogenic 
[231] 
VEGFR3 VEGF-C 
VEGFR3 (homodimer) 
VEGFR2 (heterodimer) 
Lymphangiogenesis [232] 
 sVEGFR3 Anti-lymphangiogenic [84] 
Currently characterized ligands, receptors, and their isoforms in the VEGF family. Inter-family 
interactions, function, and discovery of each VEGF family protein are given. I list the general, primary 
function for each protein; note that specific function may differ depending on cell type or physiological 
context. 
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Table 2.2: Systems biology modeling approaches.  
Computational 
Method 
Scale Functional Outputs Angiogenesis 
applications 
Reference 
Kinetic: 
Deterministic 
Molecules in 
continuum 
Temporal  
concentration 
Protein interactions 
Protein transport 
Drug PK/PD 
 
[233] 
Kinetic: 
Stochastic 
 
Molecules 
Temporal  
concentration 
Protein interactions 
Protein transport 
Drug PK/PD 
 
[233] 
 
Agent-based 
Molecular 
Cell 
Spatiotemporal agent 
dynamics 
Protein or cell motility  
Protein or cell 
interactions 
Cell proliferation 
 
[96] 
Molecular 
Modeling 
Molecular Binding potential Structural analysis 
Inhibitor identification 
[98] 
 
Finite element 
Tissue 
Fluids 
 
Continuum mechanics 
 
Hemodynamics 
Vessel sprouting 
Drug delivery 
 
[100] 
Multivariate Cell 
Tissue 
Signal-to-response Stimuli to cell response 
 
[234] 
Typical computational models used in systems biology, the scale(s) of the quantities they model (i.e. 
molecules, cell, tissue), functional output(s) given by the model, specific applications to angiogenesis, and 
references describing the methods in detail. 
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CHAPTER 3 
VEGFR1 PROMOTES CELL MIGRATION AND PROLIFERATION THROUGH PLCγ 
AND PI3K PATHWAYS 
 
3.1 Introduction 
Vascular endothelial growth factor (VEGF) is a potent angiogenesis promoter, and is 
therefore a promising target for many pathologies, including vascular disease and cancer [235]–
[239]. Despite this promise, VEGF targeted therapies are not clinically effective for many 
patients [187], [188]. As such, there is an urgent need to develop a greater understanding of how 
VEGF-promoted angiogenesis can be controlled, mechanistically, to improve the efficiency and 
specificity of current angiogenic treatments. 
VEGF receptor-1 (VEGFR1) has emerged as a predictive biomarker for anti-VEGF 
therapeutics in cancer [178], [240], [241], but its signaling mechanisms and function remain 
incompletely defined. VEGFR1 is conventionally described as a decoy receptor that does not 
produce intracellular signals [242], due to its high VEGF affinity but low phosphorylation 
compared to VEGFR2 [243]. However, emerging evidence suggests an active VEGFR1 
signaling role in angiogenesis: membrane VEGFR1 is upregulated during vascular reperfusion 
stages in ischemic tissue [201]; and VEGFR1 tyrosine kinase-deficient mice exhibit reduced 
angiogenesis in both hypoxic tumor cells and tumor endothelial cells [202][203]. Furthermore, 
VEGFR1 demonstrates tumor activity via placental growth factor (PlGF) [204], [205]; wherein, 
inhibition of this VEGFR1 specific ligand, prevents tumor growth and metastasis [206]. Given 
this emerging evidence, and the VEGFR1 biomarker role in cancer, I believe that VEGFR1 must 
have an important signaling role, and I aim to delineate it. 
36 
 
VEGFR1 signaling can be determined by systems biology: mathematically defining 
receptor signaling. The power of a mechanistic approach is its faithfulness to the biological 
structure. Towards this end, the two key signaling mechanism post-VEGFR1 ligation include: (1) 
carboxy-terminal receptor phosphorylation at specific tyrosine sites and (2) adapter binding at 
these sites. I define these as the key steps, because they structurally facilitate the second 
messenger signaling that  directs the angiogenic hallmarks of cell proliferation and migration 
[161], [244], [245]; as such, these steps may together predict those hallmarks. Indeed, there is 
evidence that tyrosine site phosphorylation is linked to cell response: cell proliferation results 
from phosphorylation at the VEGFR2 Tyr
1175
; whereas, phosphorylation at the VEGFR2 Tyr
1214
 
has been linked to cell migration [161]. Cell responses are similarly linked to adapter binding 
and adapter phosphorylation atRTK phosphor-tyrosine sites [246]–[250] While these tyrosine 
site-based and adapter-based approaches are useful to predict cell response, they are often 
analyzed separately, which does not enable a unified understanding of how RTK structure directs 
cell function [251], [252].  Therefore, computational models that integrate these key elements of 
receptor activation, would advance structure-based prediction of VEGFR1 signaling.  
Here, I predict how VEGFR1 directs cell response by developing, comparing, and 
validating a structure-based model of carboxy-terminal VEGFR1 activation and a general 
VEGFR1 activation model. The models quantitatively rank adapter protein contributions to 
VEGFR1-mediated cell migration and cell proliferation. Model comparison reveals how degrees 
of model “sloppiness” affect predictions of receptor activation and cell response. Computational 
predictions of cell response to drug treatment are validated via functional assays. Together, my 
modeling approach provides a new, validated tool for structure-based prediction of cell signaling, 
applied to grant the exigent mapping of the angiogenic receptor VEGFR1.  
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3.2 Results 
3.2.1 VEGFR1 primarily induces cell migration.  
Following VEGF binding, the initial intracellular VEGFR1 signal transduction steps 
include: receptor dimerization; autophosphorylation, a post-translational modification (PTM) of 
carboxy-terminal tyrosines; adapter binding to phospho-tyrosine residues (Fig 3.1); and adapter 
phosphorylation. To identify how the aggregated cell response depends on such site-specific 
PTMs, I models where adapter binding and PTMs occur non-specifically (nonspecific model) 
and adapter binding and PTM processes represent known receptor binding specificity (specific 
model) (Fig 3.2A). Both the nonspecific and specific models predict that VEGFR1 primarily 
induces cell migration (Fig 3.2B). This is evidenced by migration exhibiting both the highest 
integrated cell response (Fig 3.2C) and the highest phosphorylation amplitude (Fig 3.2D). The 
specific model reveals mechanistic insight into the migratory cell response: the VEGFR1 
tyrosine sites specify cell migration signaling. This is evidenced by the specific model exhibiting 
a greater contribution to migration signaling; the integrated migration response, relative to 
proliferation and degradation, increases 16% in the specific model, relative to the nonspecific 
model (Fig 3.2C). Furthermore, the migration phosphorylation amplitude increases 23% in the 
specific model, relative to the nonspecific model (Fig 3.2D). Therefore, I predict that VEGFR1 
tyrosine sites are structured to specify cell migration signaling.  
3.2.2 VEGFR1 tyrosine sites specify PLCγ, and PI3K activation through adapter binding 
competition.  
VEGFR1 tyrosine sites specify cell migration signaling through PLCγ and PI3K 
phosphorylation (Fig 3.2E). PLCγ and PI3K are the only adapters with increased integrated 
responses (Fig 3.2F) and phosphorylation amplitudes (Fig 3.2G) between nonspecific and 
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specific models. This unique increase in PLCγ and PI3K activation is due to their binding 
preference with the VEGFR1 phospho-tyrosine sites (Fig 3.1A); only two adapters bind 
VEGFR1 simultaneously (Appendix A, Table A.4-A.5): one adapter at Tyr
794
 and a second 
adapter at another tyrosine site. PI3K and PLCγ are the only adapters that bind Tyr
794
, thus 
experiencing less VEGFR1-binding competition than the other adapters, resulting in greater 
activation. This is evidenced by PLCγ and PI3K activation preferentially occurring at Tyr
794 
(Appendix A, Fig A.1). 
3.2.3 VEGFR1-promoted cell responses are regulated by coordinated PLCγ, PI3K, and 
Src activation.  
To predict which adapters primarily direct VEGFR1 cell responses, I perform sensitivity 
analyses between adapter concentrations and cell responses with the specific site model. I predict 
that cell proliferation and migration are primarily mediated by PLCγ and PI3K concentrations, in 
that order (Fig 3.3A-B, 3.3D-E). Conversely, degradation is primarily mediated by PLCγ and Src 
concentrations, in that order (Fig 3.3C, F). These three adapters direct VEGFR1 signaling in a 
coordinated fashion: increasing the PLCγ (Fig 3.4A-B), PI3K (Fig 3.4C-D), or Src (Fig 3.4E-F) 
concentration to ~2·104 molecules/cell increases phosphorylation of the other two adapters. 
Increasing PI3K (Fig 3.4C) and Src (Fig 3.4E) concentrations above ~2·104 molecules/cell 
increases the PLCγ integrated response, indicating that PI3K and Src promote PLCγ 
phosphorylation. Together with the result that VEGFR1 is structured to preferentially activate 
PLCγ and PI3K, I predict that PLCγ and PI3K mediate VEGFR1 cell responses through 
coordinated activation involving Src. 
3.2.4 Specific tyrosine site modeling captures adapter phosphorylation dynamics.  
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The specific model accurately predicts PI3K phosphorylation dynamics and magnitude in 
VEGF-treated RAW 264.7 macrophages, evidenced by the Χ2 goodness-of-fit test (Fig 3.5A) 
[253]. The specific model accurately predicts that PI3K phosphorylation is abrogated by the 
PI3K-specific inhibitor Wortmannin, while relatively unaffected by inhibiting other adapters (Fig 
3.5A). Conversely, the nonspecific model accurately predicts relative phosphorylation trends 
(Appendix A, Fig A.2), but not phosphorylation magnitudes; the nonspecific model 
underestimates PI3K phosphorylation by 81% and fails the Χ2 goodness-of-fit test (Fig 3.5A). 
Model predicted PLCγ phosphorylation shows the same trend: the site-specific model accurately 
predicts PLCγ phosphorylation given VEGF and inhibitor treatments, whereas the nonspecific 
model fails validation (Fig 3.5B). The specific model also accurately identifies which VEGFR1-
associated adapters are not critical to VEGFR1 signaling: Abl phosphorylation is not detected as 
predicted (Fig 3.5C). This validation highlights that modeling specific receptor tyrosine sites is 
essential to capture adapter phosphorylation magnitudes, and is translatable across cell lines, 
whereas the conventional approach to model a nonspecific receptor tyrosine site fails 
physiological validation. 
3.2.5 PI3K and PLCγ are critical to VEGFR1-induced cell migration.  
I validate the model prediction that VEGFR1 promotes cell migration, which is primarily 
regulated by PLCγ, followed by PI3K. I find that VEGFR1 does promote cell migration: VEGF 
induces significant RAW migration in vitro (Fig 3.6A-B). Furthermore, VEGFR1-induced 
migration is primarily regulated by PLCγ, followed by PI3K (Fig 3.6A-B). The specific VEGFR1 
tyrosine site model accurately quantifies adapter contributions to RAW migration; RAW 
migration decreases 79% in vitro with PLCγ inhibition (72% predicted) and 64% with PI3K 
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inhibition (64% predicted) (Fig 3.6B). Additionally, the model accurately identifies that Abl is 
insignificant to VEGFR1-induced migration (Fig 3.6B).  
3.2.6 VEGFR1-induced cell proliferation is primarily mediated via PLCγ.  
I validate the model prediction that VEGFR1 promotes cell proliferation, primarily 
through PLCγ activation. VEGFR1 promotes cell proliferation: VEGF induces significant RAW 
proliferation in vitro (Fig 3.6C). I validate the prediction that VEGFR1-induced migration is only 
significantly regulated by PLCγ; RAW proliferation decreases 50% in vitro with PLCγ inhibition 
(Fig 3.6C). Conversely, PI3K and Abl inhibition do not significantly affect cell proliferation, 
accurately predicted by the specific VEGFR1 site model.  
3.3 Discussion 
The VEGFR1 status as a decoy receptor may not fully capture its signaling role [178]; 
however, few studies have probed VEGFR1 signaling [242], which is difficult to map due to the 
low phosphorylation levels VEGFR1 exhibits. As VEGFR1 is a tyrosine kinase receptor, a 
receptor family known to signal through coupling with the SH2 domain of adapters [254], 
examining VEGFR1-adapter binding can offer new insight into VEGFR1 signal propagation. To 
this end, I developed and validated a receptor-adapter interaction modeling approach, which 
accurately predicts cell responses from adapter phosphorylation, and is translatable across 
receptor and cell types. Combining this modeling approach with experimental validation 
identified that VEGFR1 induces cell migration via PLCγ and PI3K pathways, and induces 
proliferation via a PLCγ pathway. 
3.3.1 Novel modeling techniques allow prediction of receptor signaling roles.  
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My modeling approach quantifies adapter phosphorylation and cell responses 
simultaneously to map unknown receptor signaling pathways. My modeling approach refines the 
receptor signaling models by integrating the pioneered approaches that accurately predict select 
adapter-receptor interactions [158], [255]–[257] and cell responses [258]–[260] from external 
stimuli. I additionally advance receptor signaling models by providing the ability to map 
unknown receptor pathways. Furthermore, I show that this approach to model specific receptor 
tyrosine sites offers physiological relevancy; both nonspecific and specific VEGFR1 tyrosine site 
models are validated when only the shape of adapter phosphorylation over time is considered 
(Appendix A, Fig A.2), but only the specific tyrosine site model accurately predicts adapter 
phosphorylation magnitudes (Fig 3.5). My modeling approach presented here is advantageous as 
it maps unknown receptor signaling from adapter activation to cell response, simultaneously, 
with high physiological relevancy. Additionally, my receptor-adapter modeling approach can be 
easily integrated into pharmacokinetic/pharmacodynamic models, which accurately quantify 
extracellular VEGF concentration dynamics in response to anti-VEGF drugs [174], [179], [261], 
to provide a clinically relevant platform to explore how anti-VEGF drugs mediate VEGFR 
signaling: through altering extracellular VEGF concentrations, VEGF-VEGFR interactions, and 
subsequent intracellular VEGFR signaling. Such a model integration would overcome one of the 
major challenges for developing personalized, clinically relevant computational platforms 
reviewed in [211], [262]: providing a multiscale model to comprehensively investigate biological 
systems; in this case, comprehensively modeling receptor signaling at the tissue macroscale and 
intracellular microscale.  
3.3.2 qFlow cytometry accurately quantifies membrane receptors.  
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My ability to accurately quantify VEGFR1 signaling highlights the power of integrating 
experiment and computation to provide new biology insight: empirical evidence defined 
VEGFR1-adapter reactions, kinetics, and concentrations for the model, which in turn provided 
testable VEGFR1 signaling predictions that I confirmed experimentally. This first step, model 
parameterization, is essential to develop physiologically relevant models, as previously described 
[91], [263], [264]. VEGFR concentration parameterization was achieved with quantitative flow 
(qFlow) cytometry [201], [265], [266], a recently established high-throughput approach that 
detects receptor expression with a fluorescent affinity probe and quantifies absolute receptor 
levels using fluorescent calibration standards [267]. While qFlow cytometry is becoming an 
essential tool for parameterizing receptor concentrations in computational models [158], [159], 
[163], [174], [176]–[179], analogous methods for quantifying other receptor signaling 
parameters, such as adapter phosphorylation rates, are not well established. As such, most 
computational models contain parameters that are estimated or generalized across multiple 
species or interactions [268]computational models; Bose and Janes recently developed one such 
method for high-throughput characterization of signal molecule dephosphorylation kinetics via 
phosphatase activity [269]. Development of such high-throughput methods to completely 
parameterize receptor signaling models, from species concentrations to specific kinetics for 
every interaction, would unlock additional options for tuning receptor signaling, such as by 
targeting specific phosphatases, while maintaining high physiological relevancy.      
3.3.3 VEGFR1 preferentially activates PLCγ in burst activation to induce cell migration, 
possibly through Ca
2+
 signaling.  
I show that VEGFR1-induced PLCγ activation is required for cell migration, and 
hypothesize this VEGFR1-PLCγ-mediated migration involves Ca
2+ signaling. PLCγ 
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phosphorylation is known to activate Ca2+ influx [270], [271] in oscillatory bursts [272]–[275]. 
Furthermore, directed cell migration requires Ca2+ pulses near the leading edge of the cell [276]–
[278]. From this prior knowledge, combined with the delta function-like PLCγ activation 
observed in the model, I hypothesize that VEGFR1 phosphorylates PLCγ in quick bursts to 
induce Ca2+ pulses and direct cell migration. This burst PLCγ activation could explain how cells 
migrate towards a VEGF gradient, with a possible mechanism being as follows: (1) VEGF binds 
plasma membrane VEGFR1 on the cell facing the gradient; (2) VEGFR1 recruits and 
phosphorylates PLCγ; and (3) phosphorylated PLCγ causes Ca
2+ pulses by activating Ca2+ 
channels, a well-established mechanism [279]–[281] reviewed by Mikoshiba [282], initiating 
migration towards the VEGF gradient. This mechanism is further supported by experimental data 
showing that Ca2+ pulse following VEGF simulation is required for HUVEC migration [280]. As 
the extent of directed cell migration is dependent on growth factor gradient patterns [283], I 
hypothesize that VEGFR1-PLCγ activation acts as a VEGF gradient sensor to determine both cell 
migration direction and magnitude. Future work experimentally probing PLCγ -mediated 
migration, is necessary to validate this mechanism.   
3.3.4 Ca2+ signaling may indirectly regulate PI3K activation by VEGFR1.  
I identified PI3K as a primary adapter directing VEGFR1-mediated cell migration. 
Primarily, PI3K is known to promote cell migration through Akt activation [284], [285], which 
also involves Ca
2+
 signaling; PI3K/Akt activation translocates Ca
2+ 
channels to the cell 
membrane, inducing Ca
2+
 entry into cells, and subsequent cell migration [286]. However, PI3K 
activation does not induce Ca
2+
 signaling in HUVECs [287]; rather, PI3K is activated by Ca
2+
 to 
promote HUVEC migration [288]. Thus, PI3K may play an important role in indirectly 
activating Ca
2+
 signaling and HUVEC migration.  
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3.3.5 The PLCγ, PI3K, and Src dependent relationship may form a Ca
2+ signaling 
regulatory loop.  
I observed a dependent relationship between VEGFR1-induced PLCγ, PI3K, and Src 
phosphorylation. As PI3K and PLCγ cooperate to initiate Ca
2+ signaling [289], I hypothesize that 
PI3K, PLCγ, and Ca
2+ have a dependent relationship to robustly mediate VEGFR1-induced cell 
migration. Furthermore, PLCγ induced Ca
2+ signaling phosphorylates Src [290], and Src 
phosphorylates PLCγ [287], [290], [291] and PI3K [292]–[294]. Thus, I hypothesize from these 
studies and my results that VEGFR1 is structured to preferentially activate a PLCγ, PI3K, and 
Src regulatory loop mediating Ca2+ signaling (Fig 3.7), and subsequent cell migration. 
3.3.6 VEGFR1-promoted hematopoietic progenitor cell migration may be required for 
tumor cell metastasis.  
The strong VEGFR1 migratory signal I identify here indicates VEGFR1 signaling may be 
required for hematopoietic progenitor cell (HPC) migration to form pre-metastatic niche clusters. 
Metastasis from the primary tumor site requires circulating tumor cells to extravaste into 
secondary sites [295]. Prior to this process, the tumor primes pre-metastatic niches, sites 
receptive to recruiting circulating tumor cells, to direct at which secondary sites metastasis 
occurs [296]. These pre-metastatic niches are characterized by clustering of VEGFR1 positive 
HPCs; inhibiting VEGFR1 on HPCs prevents pre-metastatic niche formation and tumor cell 
metastasis [297]. This effect of pre-metastatic niche formation being prevented with VEGFR1 
inhibition may be explained by HPC migration requiring VEGFR1 signaling; thus, inhibiting 
VEGFR1 would prevent HPC migration, HPC clustering, and subsequent tumor cell metastasis. 
Furthermore, Akt activation has been implicated in macrophage-assisted cancer cell invasion 
[298], supporting my hypothesis that VEGFR1-PI3K-Ca
2+
 signaling (Fig 3.7) promotes 
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macrophage migration. Therefore, targeting VEGFR1-induced HPC migration may be a 
therapeutic option to prevent tumor cell metastasis. 
3.3.7 VEGFR1 can be comprehensively modeled by incorporating adapter-adapter 
interactions and specific phosphatases.  
My modeling approach accurately predicted adapter phosphorylation and cell responses 
by quantifying complex formation between specific VEGFR1 tyrosine sites and single adapters, 
with adapter dephosphorylation occurring through a generalized phosphatase. Building upon this 
validated model to include adapter-adapter interactions and specific phosphatases would 
comprehensively represent VEGFR1 signaling. Modeling adapter-adapter interactions would 
identify how VEGFR1 signaling is directed through adapter cooperativity; adapter-adapter 
interactions occur via adapter SH3 domains [299] to form larger signaling complexes that direct 
differential cell outcomes [300], [301]. The ability to accurately model multi-adapter complex 
formation with VEGFR1 is currently limited however, as no known experimental or 
computational studies have mapped the adapter-adapter interactions downstream VEGFR1. This 
limitation may be overcome by identifying VEGFR1-associated adapter-adapter interactions 
from VEGF-induced protein phosphorylation dynamics, a predictive approach validated with the 
epidermal growth factor receptor signaling axis [302].  
Modeling specific phosphatases would identify additional VEGFR1-targeting 
therapeutics; since different phosphatases bind specific adapters to dynamically regulate receptor 
signaling [303], VEGFR1-induced adapter phosphorylation and cell responses could be directed 
by targeting specific phosphatases. The ability to model specific phosphatases is currently 
limited however, as the specific phosphatases involved in VEGFR1 signaling, and their adapter 
interaction kinetics, have not been determined. This limitation may be overcome using the high-
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throughput assay for identifying phosphoprotein-specific phosphatases and kinetics developed by 
the Janes lab [269]. Overall, incorporating adapter-adapter interactions and phosphatase 
specificity into the VEGFR1 model would provide further insight into how VEGFR1 signaling is 
directed systemically, and identify additional proteins or interactions that can targeted to tune 
VEGFR1 signaling. 
3.3.8 Conclusions.  
My modeling approach has identified that VEGFR1 actively promotes cell migration and 
proliferation primarily via the PLCγ and PI3K pathways, and has posited a new hypothesis that 
adapter coordination and Ca
2+
 signaling may be regulate this VEGFR1-mediated migratory 
response. These findings critically advance our understanding of angiogenesis by providing a 
structurally-based mechanism for VEGFR1 function. These findings and my modeling platform 
also offer mechanistic guidance for developing therapeutics targeting VEGFR1 signaling. This 
also represents a paradigm shift, since VEGF, generally, and VEGFR2 are primary targets for 
drug discovery. This modeling approach provides a foundation to fully understand receptor 
signaling mechanisms, an essential step to develop effective angiogenic therapeutics for vascular 
diseases and cancers. 
3.4 Materials and Methods 
3.4.1 Computational models.  
VEGFR-adapter interaction models are defined by ordinary differential equations and 
solved with the SimBiology toolbox in MATLAB. In general, the VEGFR-adapter scheme 
interaction scheme follows: 
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   (3.1) 
for each adapter A and both VEGFRs, where PTPN are phosphatases. Model predicted adapter 
phosphorylation in HUVECs shows good agreement to previous experimental data (Appendix A, 
Fig A.2). VEGFR1 and VEGFR2 are both modeled for this validation (Fig 3.1), as HUVECs 
express both receptors. Following this validation, I examine adapter-VEGFR1 interactions 
specifically to determine the VEGFR1 function. See Appendix A for details. 
3.4.2 Protein concentrations.  
HUVEC protein concentrations are determined by Western blot intensity, relative to a 
known protein concentration, assuming a linear relationship between protein band intensities 
(Appendix A, Table A.1). I assume PTPN acts as an “infinite reservoir”; the PTPN concentration 
is sufficiently high to not be a limiting species in any reaction. 
3.4.3 Kinetics parameters. 
Each adapter is assumed to have the same interaction kinetics (on-rate and off-rate) for 
both VEGFR1 and VEGFR2, and is the same for all tyrosine sites (Appendix A, Table A.2). 
Adapter-VEGFR interaction kinetics are assumed identical to adapter-EGFR interaction kinetics. 
If adapter-VEGFR or adapter-EGFR interaction rates are unavailable, I assume the rates between 
the SH2 domain of the adapter and a phosphorylated tyrosine kinase fragment is identical to the 
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adapter-VEGFR rates. (4) I assume a 1 pL cell volume, to convert rates from M to 
molecules/cell.  
3.4.4 Adapter phosphorylation.  
All adapter phosphorylation rates (kp) are 0.01 s
-1
, so adapter phosphorylation is only 
dependent on VEGFR interaction kinetics. Adapters do not undergo auto-dephosphorylation, and 
are only dephosphorylated by phosphatases. A generalized phosphatase (PTPN) binds and 
dephosphorylates all adapters, with the same interaction kinetics and dephosphorylation rate. 
3.4.5 Predicting cell response from adapter phosphorylation.  
The degradation cell response is identical to c-Cbl phosphorylation; only c-Cbl 
contributes to a degradation cell response. Proliferation and migration cell responses are 
determined by a weighed sum of adapter phosphorylation. Weights are calculated by the 
contribution each adapter provides towards the specific cell response, as determined 
experimentally (Appendix A, Table A.3). 
3.4.6 Tyrosine site specificity. 
Multiple adapters can bind a single receptor if the combined size of the adapters is 
smaller than the available space between tyrosine sites (Appendix A, Table A.4-A.5). Adapters 
bind the receptor in 1-dimension (the y-direction). Total adapter sizes are determined by 
measuring the maximal space the adapter crystal structure occupies in the y-direction. The center 
of an adapter binds a VEGFR tyrosine site; thus, the amount of space a receptor occupies 
between VEGFR tyrosine sites is half the total adapter size. I measure the average distance 
between VEGFR amino acids, and use that distance to determine the space between VEGFR 
tyrosine sites. For example, the distance between individual amino acids in VEGFR1 was 
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measured as 0.171 Å/amino acid, so the distance between tyrosine sites Tyr
1242
 and Tyr
1333
 is 
15.6 Å. 
3.4.7 Experimental Methods. 
Experiments were performed using murine RAW 264.7 macrophages due to their high 
VEGFR1 expression (Appendix A, Fig A.3), making them an ideal cell line to study VEGFR1 
signaling. RAW 264.7 macrophages were cultured in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin 
(PS). Cells were maintained in a humidified incubator at 37 
o
C and 5% CO2. Murine VEGF-A164 
was purchased from BioLegend, and all inhibitors (Wortmannin, U73122, and Imatinib 
Mesylate) were purchased from Selleckchem. ELISA kits were purchased from Assay 
Biotechnology. The MTT cell proliferation assay kit was purchased from Thermo Fisher 
Scientific.  
3.4.8 Quantifying protein phosphorylation.  
RAWs were seeded into a 96-well plate, stimulated with VEGF or any inhibitors for 
specified times, and the phosphorylated and total proteins of interest (PLCγ, PI3K, and Abl) were 
measured using ELISAs. See SI Materials and Methods for details.  
3.4.9 Cell migration assays.  
RAWs were seeded into a 12-well plate, scratched with a pipette tip, treated with VEGF 
or any inhibitors, and imaged at 0 h and 24 h to characterize migration. See SI Materials and 
Methods for details. 
3.4.10 Cell proliferation assays.  
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RAWS were seeded into a 96-well plate, stimulated with VEGF or any inhibitors, and 
cell proliferation was measured after 24 h using a MTT assay. See SI Materials and Methods for 
details.  
3.4.11 Flow cytometry.  
RAWs were labeled with Phycoerythrin (PE)-conjugated monoclonal antibodies specific 
to VEGFR1 or VEGFR2. Fluorescence given off by PE was captured in flow cytometry, and 
converted to VEGFR level per cell (Appendix A, Fig A.3). See SI Materials and Methods for 
details. 
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3.5 Figures 
 
Fig 3.1: VEGFR-adapter interaction schematics.  
Adapters bind specific tyrosine (Tyr) sites on (A) VEGFR1 and (B) VEGFR2 (Appendix A, Table A.4). 
VEGFR1 and VEGFR2 kinase domain crystal structures were used to measure the distance between 
individual VEGFR amino acids. This measurement, along with adapter size measurements (Appendix A, 
Table A.5), were used to map the adapters and Tyr sites that allow multiple adapters to bind a VEGFR 
simultaneously. 
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Fig 3.2: The VEGFR1 structure preferentially activates PLCγ and PI3K.  
(A) Schematics for the VEGFR1-adapter interaction models: (left) adapters bind a single nonspecific 
VEGFR1 tyrosine site versus (right) adapters binding specific VEGFR1 tyrosine sites. Here adapters are 
shown in a generalized form, labeled A and B, P represents a phosphorylated receptor Tyr site, and the 
plus symbol indicates an adapter binding the phosphorylated receptor Tyr site. VEGFR1 signaling was 
modeled in HUVECs to determine (B) VEGFR1-induced cell response dynamics, (C) the integrated cell 
responses, and (D) cell response phosphorylation amplitudes. Likewise, (E) VEGFR1-mediated adapter 
phosphorylation dynamics in HUVECs are analyzed to quantify (F) integrated adapter responses and (G) 
adapter phosphorylation amplitudes. 
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Fig 3.3: VEGFR1-induced cell migration and proliferation are primarily directed by PLCγ and 
PI3K concentrations.  
(A-C) Integrated responses and (D-F) phosphorylation amplitudes for each cell response were quantified 
with respect to adapter concentration, using the specific VEGFR1 tyrosine site model. 
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Fig 3.4: PLCγ, PI3K, and Src form a coordinated activation loop with one another.  
The integrated responses and phosphorylation amplitudes of all adapters were examined with altering (A-
B) PLCγ concentration, (C-D) PI3K concentration, and (E-F) Src concentration, using the specific 
VEGFR1 tyrosine site model. Adapter concentrations were ranged between 10
2
 - 10
5
 molecules/cell. The 
vertical gray dashed lines indicate the physiological adapter concentration in HUVECs (Appendix A, 
Table A.1). 
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Fig 3.5: VEGFR1 phosphorylates PI3K and PLCγ with model predicted dynamics.  
(A) PI3K, (B) PLCγ, and (C) Abl phosphorylation in RAWs were quantified with ELISAs at multiple 
time points given treatment with VEGF-A164 (50 ng/mL), 100 nM Wortmannin (PI3K inhibitor), 10 µM 
U73122 (PLCγ inhibitor), and 6 µM Imatinib Mesylate (Abl inhibitor). Data is represented as the mean 
phosphorylated over mean total protein (p/t) ratio ± standard error of the mean (SEM) for each treatment 
type and treatment time; here SEM is the sum of the phosphorylated and total protein SEMs. The p/t ratio 
given inhibitor treatment specific to the protein of interest was subtracted as background for each 
treatment time. Predicted adapter phosphorylation with a nonspecific (dashed line) and specific (solid 
line) VEGFR1 tyrosine sites are shown compared to experimental data (open circles). Goodness of fit is 
tested by the Χ2 goodness-of-fit test [253]. 
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Fig 3.6: PLCγ and PI3K regulate VEGFR1-induced cell responses in vitro.  
(A) RAW migration was measured in wound healing assays at 0 h and 24 h post scratch. Scale bars 
represent 50 µm. (B) Analyzed wound healing assays show that inhibiting PLCγ or PI3K significantly 
decreases VEGF-induced RAW migration. (C) PLCγ inhibition significantly decreases VEGF-induced 
RAW proliferation, measured with MTT assays. Treatments for all experiments were: 50 ng/mL VEGF-
A164, 10 µM Wortmannin (PI3K inhibitor), 10 µM U73122 (PLCγ inhibitor), and 10 µM Imatinib 
Mesylate (Abl inhibitor). All experiments were performed in triplicate, and data is represented as mean ± 
SEM. Experimental significance is given at p < 0.05. (B-C) The predicted maximum reduction in cell 
response from the model is given for each inhibitor treatment (red line). Dashed grey lines outline the 
range corresponding to 10% variation in cell migration given VEGF treatment alone; inhibitor treatments 
are predicted to be significant by the model if the predicted cell migration lies outside this range. 
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Fig 3.7: VEGFR1 preferentially activates PLCγ, PI3K, and Src, possibly to form a Ca
2+ 
signaling regulatory loop.  
My simulations predict that VEGFR1 tyrosine sites are structured to preferentially associate with 
PLCγ or PI3K at Tyr
794
 and Src at Tyr1169 or Tyr1213, simultaneously. I theorize that this PLCγ, 
PI3K, and Src activation scheme by VEGFR1 forms a Ca2+ signaling regulatory loop, as 
depicted. Arrow color indicates adapter or Ca
2+ signal activation by VEGFR1 (solid gray), PLCγ 
(blue), PI3K (pink), Src (cyan), or through Ca2+ signaling (dashed gray). Additional VEGFR1 
binding sites and adapter association are not shown. 
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CHAPTER 4 
INTEGRATIVE META-MODELING IDENTIFIES ENDOCYTIC VESICLES, LATE 
ENDOSOMES, AND THE NUCLEUS AS THE CELLULAR COMPARTMENTS 
PRIMARILY DIRECTING RTK SIGNALING 
 
4.1 Introduction 
Receptor signal transduction is critical to many pathologies, including cancers [304], 
[305] and vascular diseases [306], [307]. Typically, membrane receptors are targeted to control 
signal transduction, as they are the initial mediators of eliciting cell responses from extracellular 
signal transducers (e.g., ligands) [301], [308]. While signal transduction pathways have been 
established for specific membrane receptors [309]–[312], how cell physiology directs signal 
transduction fundamentally, for any receptor in general, remains undefined. Delineating cell 
physiology effects on receptor signaling would result in a “signaling template” that both governs 
signaling fundamentals and may be tuned to account for receptor-specific spatiotemporal  
dynamics [313], [314]. Engineering such a signaling template would offer improved signal 
mapping, while enabling receptor-based signaling control, critical for treating pathological 
conditions.  
Systems biology allows for this delineation between cell physiology and receptor 
signaling. Systems biology studies have identified that endocytosis directs receptor signaling to 
primarily occur intracellularly [195], [315]: cells exhibiting prolonged receptor signaling and 
enhanced cell responses exhibit less receptor recycling, leading to intracellular ligand-receptor 
accumulation, [316], [317]. Experimental studies validated these computational predictions; high 
epidermal growth factor receptor (EGFR) phosphorylation, along with phosphorylated Shc, 
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Grb2, and mSOS signaling molecules, were identified within endosomes [318]. Such studies 
advanced early views that endocytosis only functioned to terminate membrane receptor signaling 
[315], derived from experimental findings that while ligand-bound receptors traffic to lysosomes, 
where protein degradation occurs, ~10-fold faster than unligated receptors [319]–[321]. Thus, 
computational systems biology provides valuable insight into receptor signaling; extending these 
studies to model how cell physiology and endocytosis direct intracellular-based receptor 
signaling, fundamentally, would further refine the knowledge of receptor signaling mechanisms.  
Understanding how endocytosis fundamentally directs intracellular receptor signaling 
requires receptor-specific endocytosis mechanisms to be delineated. This delineation requires 
identifying the signaling mechanisms common to all receptor types. However, the ability to 
identify these common receptor signaling mechanisms from experimental observations is 
limited; intracellular-based receptor signaling studies have examined EGFR almost exclusively 
[196], [310], [322], providing insights that may not be extendable to other receptor types. 
Therefore, conducting a computational meta-analysis across multiple receptor families will allow 
the signaling mechanisms common to different receptors to be identified.  
I develop a computational endocytosis signaling template to conduct a meta-analysis 
across eight tyrosine kinase receptors (RTKs): EGFR, FGFR1, IGFR1, PDGFRα, PDGFRβ, 
VEGFR1, VEGFR2, and Tie2. I delineate the complex endocytosis mechanisms to understand 
intracellular RTK signaling in general, by examining how cell (compartment volume, trafficking 
kinetics, and pH; Table 1) and ligand-receptor physiology (ligand/receptor concentration and 
interaction kinetics; Table 2) direct signaling. Specifically, I model RTK translocation post-
ligand simulation: internalization and trafficking through intracellular compartments (Fig 4.1). I 
weigh receptor phosphorylation, a post-translational modification, across each endocytic 
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compartment. I predict that RTK signaling primarily occurs within endocytic vesicles, due to 
their low volume potentiating ligand concentrations. I also predict that all RTKs undergo nuclear 
translocation dependent on extracellular ligand concentration, requiring a late endosome 
pathway. Overall, this study provides fundamental insights into RTK signaling, and an 
endocytosis signaling template that can be applied to probe specific RTK signaling, or test RTK 
therapeutics.   
4.2 Results 
4.2.1 RTK phosphorylation primarily occurs intracellularly.  
Quantifying compartmentalized receptor signaling reveals that RTKs primarily signal 
within endocytic vesicles, comprising > 43% the total receptor signaling within the cell, for all 
eight RTKs modeled (Table 2). Conversely, membrane signaling is relatively low, giving < 1% 
the total receptor signaling for all eight RTKs (Table 2). This indicates that essentially all RTK 
signaling within a cell stems from intracellular receptors. 
4.2.2 Absolute membrane signaling is dependent on the RTK.  
While these eight RTKs follow the same signaling trend, receptor signaling primarily 
occurring intracellularly, absolute receptor signaling, given by integrated response, is highly 
variable. Nuclear signaling ranges between 3.3% - 27% the total receptor signaling within the 
cell, given by FGFR1 and EGFR, respectively.(Table 2). Absolute receptor signaling is directed 
by the RTK complex level, which is defined as 
d
[R][L]
K
, where [R] is receptor level, [L] is ligand 
concentration, and Kd is the ligand-receptor dissociation constant. FGFR1 has the lowest nuclear 
signaling since it has the lowest complex level amongst the eight RTKs. Conversely, EGFR has a 
large complex level, leading to high nuclear signaling (Table 2). This computational signaling 
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template thus allows receptor signaling importance to be weighed relative to other receptors 
within each cellular compartment; amongst these eight RTKs, nuclear signaling is ranked as: 
EGFR > IGFR1 > PDGFRα > VEGFR1 > VEGFR2 > PDGFRβ > Tie2 > FGFR1.  
4.2.3 Endocytic compartmentalization leads to two primary receptor signaling trends.  
To understand how receptor signaling is dynamically regulated by endocytic 
compartmentalization, I examine Ang2-Tie2 signaling, as a representative axis for these eight 
RTKs. I find that receptors associated with the membrane (Fig 4.2A), endocytic vesicles (Fig 
4.2B), early endosomes (Fig 4.2C), and recycling endosomes (Fig 4.2D) have similar activation 
and decay constants, implying these compartments promote similar receptor signaling dynamics. 
Likewise, receptors associated with late endosomes (Fig 4.2E) and lysosomes (Fig 4.2F) have the 
same activation and decay constants. The nucleus is the only compartment that does not follow 
one of these two signaling dynamics (Fig 4.2G). These activation and decay constants define two 
receptor dynamic trends: the membrane, endocytic vesicles, early endosomes, and recycling 
endosomes promote rapid receptor signaling, whereas late endosomes and lysosomes promote 
slow receptor signaling. 
4.2.4 Phosphorylated receptors primarily associate with endocytic vesicles and late 
endosomes after ligand stimulation.  
Receptor signaling compartmentalization reveals that receptor phosphorylation primarily 
occurs within endocytic vesicles early, and late endosomes late, after ligand stimulus. Within 5 
minutes after ligand stimulus, ~22% the total cell receptors are phosphorylated within endocytic 
vesicles, whereas < 1% are within all other compartments (Fig 4.2H). Conversely, 3 hours after 
ligand stimulus, ~11% the total cell receptors are phosphorylated within late endosomes, whereas 
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< 5% are within all other compartments (Fig 4.2H). Thus, phosphorylated receptors 
preferentially associate with endocytic vesicles immediately following ligand stimulation, 
switching to late endosomes at later time points. 
4.2.5 Membrane receptors facilitate burst signaling whereas endocytic receptors facilitate 
sustained signaling.  
From these results that receptor phosphorylation primarily occurs within endocytic 
vesicles, I hypothesize that the small endocytic vesicle volume (Table 4.1) facilitates high ligand 
concentration and strong ligand-receptor interactions, causing high receptor phosphorylation. To 
test this hypothesis, I compare receptor phosphorylation within endocytic vesicle to membrane 
receptor phosphorylation (Fig 4.3A). At the membrane, less than 1% the total receptors are 
phosphorylated 60 minutes after ligand stimulation (Fig 4.3B). Conversely, ~80% the total 
receptors within a single endocytic vesicle are phosphorylated at equilibrium, reached within 5 
minutes after ligand stimulation (Fig 4.3C). Subsequently, the same number of receptors within 
endocytic vesicles produces substantially greater signaling than at the membrane: 5 orders of 
magnitude higher at 2 hours after ligand stimulation (Fig 4.3D). This implies that the low 
endocytic vesicle volume does concentrate ligand signaling, facilitating strong ligand-receptor 
interactions, and presenting endocytic vesicles as the chief signaling compartment.  
4.2.6 Nuclear translocation requires a late endosome pathway.  
To understand how receptors undergo nuclear translocation, I observe how nuclear 
signaling is affected by blocking endocytic pathways (Fig 4.4). Nuclear translocation is most 
effectively inhibited by blocking receptor trafficking from late endosomes to the nucleus, 
decreasing nuclear signaling 96% (Fig 4.4). Likewise, nuclear translocation is most effectively 
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promoted by blocking receptor trafficking from late endosomes to lysosomes, increasing nuclear 
signaling 133% (Fig 4.4). Interestingly, blocking the early to late endosomes pathway has a 
lesser effect on nuclear translocation, despite this pathway being required for receptor 
association with late endosomes. Therefore, late endosome trafficking directs nuclear 
translocation. 
4.2.7 Compartmentalized receptor signaling is best regulated by the extracellular ligand 
concentration.  
To identify how the RTK parameters (receptor level, ligand concentration, and ligand-
receptor kinetics) mediate compartmentalization and signaling for a single RTK, I examine 
Ang2-Tie2 signaling in response to altering RTK parameters (Fig 4.5). While ligand-receptor 
kinetics direct membrane signaling (Fig 4.5A), receptor signaling in all intracellular 
compartments are unaffected by altering ligand-receptor kinetics (Fig 4.5B-E). Receptor level 
only affects nuclear and endocytic vesicle receptor signaling, evidenced by an eight order of 
magnitude increase in receptor increasing nuclear signaling from 3% to 22% (Fig 4.5E). 
Conversely, ligand concentration highly regulates receptor signaling in all intracellular 
compartments (Fig 4.5B-E), evidenced by increasing the ligand concentration eight orders of 
magnitude reducing endocytic vesicle signaling from 73% to 43% (Fig 4.5B). Thus, 
compartmentalized signaling for a single RTK is directed by the extracellular ligand 
concentration.  
4.2.8 Nuclear based receptor signaling is best regulated by ligand concentration.  
To test if extracellular ligand concentration directs intracellular signaling across all eight 
RTKs, I perform a correlation analysis between nuclear signaling and RTK parameters (Fig 4.6). 
64 
 
Nuclear signaling has low correlation with the receptor level (Fig 4.6A, R
2
 = 0.08) and the 
ligand-receptor dissociation constant (Fig 4.6B, R
2
 = 0.17), implying that these parameters have 
low weight in determining nuclear-based RTK signaling. Conversely, extracellular ligand 
concentration better characterizes nuclear signaling (Fig 4.6C, R
2
 = 0.47), indicating the highest 
weight amongst the three RTK parameters. This correlation analysis predicts that increasing the 
extracellular ligand concentration one order of magnitude will increase nuclear signaling 3.2-
fold. Furthermore, the complex level, which comprises the other three parameters, provides a 
good overall predictor of nuclear signaling (Fig 4.6D, R
2
 = 0.75), confirming that nuclear 
signaling is mediated by these three RTK parameters. This trend that receptor level and ligand-
receptor dissociation constant have low weight, versus extracellular ligand concentration having 
high weight, in mediating receptor signaling holds for all endocytic compartments (Appendix B, 
Fig B.2-B.5). Thus, the extracellular ligand concentration regulates compartmentalized receptor 
signaling across all eight RTKs.  
4.3 Discussion 
My integrative RTK meta-modeling approach is the first time that these eight RTKs, all 
of which are critical to disease (e.g., cancer [304], [305], [323], [324], cardiovascular disease 
[306], [307], stroke [325], [326]) have been comparatively modeled. This meta-modeling led to 
five important findings: (1) RTK signaling primarily stems from endocytic vesicles, whereas 
membrane signaling is relatively low; (2) high receptor activation within endocytic vesicles is 
due to their low volume, facilitating ligand enrichment; (3) all RTKs exhibit nuclear 
translocation, requiring a late endosome pathway; (4) signaling between RTK type and cellular 
compartments can be ranked; (5) the extracellular ligand concentration directs 
compartmentalized RTK signaling. These findings can be applied to quantify receptor signaling, 
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understand how RTK signaling directs cell response, and optimize RTK therapeutics targeting 
endocytic pathways. 
4.3.1 Targeting intracellular-based signaling is critical to direct RTK signaling.  
My signaling template predicts that RTK signaling primarily occurs within endocytic 
vesicles. This trend holds for all eight RTKs tested, regardless of receptor level or ligand-
receptor interaction kinetics: receptor level varies 29-fold, and ligand-receptor dissociation 
constant varies 1.0·10
3
-fold, across these eight RTKs [178], [327]–[334]. Experimental studies 
have shown that intracellular-based signaling is important for the RTKs tested here, without 
identifying which specific compartment signaling stems from: ERK phosphorylation is reduced 
by inhibiting EGFR [335], FGFR1 [336], IGFR1 [337], PDGFRβ [338], or VEGFR2 [339] 
endocytosis. Similarly, PDGFRα accumulation in endocytic vesicles increases ERK 
phosphorylation [340]. Additionally, experimental studies show that RTK inhibitors that 
penetrate the plasma membrane are more effective at reducing signaling [341], [342]. While no 
experimental studies have currently investigated intracellular Tie2 signaling to my knowledge, 
my simulations indicate intracellular-based Tie2 is important to Tie2 signaling. My results and 
these previous experimental studies indicate that targeting endocytic vesicle receptors is 
necessary to effectively regulate RTK signaling.  
4.3.2 Application to understanding cancer drug resistance.  
My finding that RTK phosphorylation primarily occurs within endocytic vesicles is also 
useful for understanding cancer cell drug resistance. In particular, I predict that drugs target 
membrane receptors, but not endocytic vesicle receptors, would be sub-optimal. Literature offers 
an example of such failed-targeting in gefitinib, a small molecule inhibitor that blocks the EGFR 
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ATP binding site and is used to treat non-small cell lung cancer (NSCLC). This drug is only 
effective in cell types where it inhibits intracellular-based EGFR signaling [343], [344], such as 
in NSCLC PC9 cells where gefitinib inhibits endocytosis. Conversely, QG56 cells have aberrant 
endocytosis natively and are thus gefitinib-resistant; gefitinib can only inhibit membrane-EGFR 
in QG56 cells [343]. Thus, my simulations offer guidance in RTK inhibition, suggesting 
improved efficacy when inhibiting intracellular receptor phosphorylation, while offering insight 
into reduced drug efficacy. 
4.3.3 Temporal implications for therapeutics.  
I identified two distinct receptor phosphorylation dynamics across endocytic 
compartments, characterized by (1) rapid receptor phosphorylation and (2) slow receptor 
phosphorylation dynamics. These intracellular signaling dynamics have also been observed in 
experimental studies [315], [345]–[347]. PDGFRs [347] and VEGFR2 [348] are primarily 
phosphorylated within endosomal compartments early, 30 minutes, then shift to downstream 
endocytic compartments late, 2 hours, following ligand stimulation. However, these studies do 
not differentiate receptor phosphorylation at different endocytic compartments, which is a 
fundamental advancement of my model. This pattern highlighted by my model is particularly 
useful for optimizing time-dependent drug delivery [349]–[351]. Specifically, drug regimens 
targeting endocytic vesicle signaling would need to be initiated and effective within 30 minutes 
following ligand stimulus, when receptor signaling occurs. Thus, these identified compartment 
receptor signaling dynamics can be applied to optimize drug delivery regimes.  
4.3.4 Receptor signaling can be controlled by targeting endocytic vesicles or late 
endosomes.  
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The results that receptor signaling primarily occurs from endocytic vesicles implies that 
receptor signaling can be regulated by directing receptor trafficking. Endocytic vesicle signaling 
could be prevented by treating cells with dynasore to inhibit dynamin, preventing receptor 
endocytosis and retaining receptors at the membrane [352], [353]. Conversely, phorbol esters 
could be used to increase RTK signaling [354], [355]; stimulating BHK-21 cells with phorbol 
esters increases the number of endocytic vesicles up to 2-fold [356]. Alternatively, neomycin 
prevents endocytic vesicle fusion into early endosomes, retaining receptors within endocytic 
vesicles [357], [358]. Similarly, nuclear translocation can be directed by targeting Rab GTPases 
to block late endosome pathways [359]–[362]; mutating Rab7 prevents VEGFR2 endocytosis to 
late endosomes [359]. Directing nuclear trafficking is desirable as nuclear translocated receptors 
potentiate cell responses by promoting gene expression [363]–[368]. Thus, directing receptor 
trafficking, rather than directly alter receptor signaling, may be a viable therapeutic option. 
4.3.5 Application to RTKs based primarily intracellularly.  
My signaling template not only provides insight into generalized RTK signaling, but can 
also be applied to specific cases, such as targeting RTKs that are primarily localized 
intracellularly. Approximately half the cellular VEGFR2, often targeted to inhibit tumor 
angiogenesis [369], [370], is localized within endosomes [371], [372]. This intracellular pool is 
critical to VEGFR2 function, as facilitating cell uptake of a VEGFR2 antibody, by loading it into 
liposomes, decreased tumor volume 77% after compared to extracellularly applying the 
VEGFR2 antibody alone [373]. My signaling template easily allows this intracellular VEGFR2 
pool to be modeled, allowing additional optimization and testing for VEGFR2 therapeutics. 
4.3.6 Conclusions.  
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Here I present a computational meta-analysis tracking RTK endocytosis and 
phosphorylation. I find that across eight RTKs, receptor phosphorylation primarily occurs 
intracellularly, directed primarily by the extracellular ligand concentration. Furthermore, I find 
significant nuclear translocation of membrane receptors through a late endosome pathway, 
indicating that preventing endocytosis through late endosomes, such as with Rab7 inhibition, will 
prevent nuclear translocation and subsequent gene expression. Overall, this study provides a 
signaling template for studying specific RTKs or endocytic pathways, allowing therapeutic 
investigation and drug delivery optimization. 
4.4 Materials and Methods 
4.4.1 Computational RTK endocytosis model.  
Cell compartment volumes (Table 4.1), pH (Table 4.1), and trafficking kinetics 
(Appendix B, Table B.1) are held the same for all RTKs. Ligand concentrations, receptor 
concentrations, and interaction kinetics are RTK specific (Table 4.2) [177], [327], [328], [330]–
[334], [374]. Trafficking kinetics are determined by fitting to experimental data that quantify 
receptor localization to the membrane (Appendix B, Fig B.1A), nucleus (Appendix B, Fig B.1B), 
endosomes (Appendix B, Fig B.1C-D), and lysosomes (Appendix B, Fig B.1E-F). The best fit 
parameters were found by minimizing the global Chi-square between experimental data and 
simulation: 
2n
i i
i 1 i
ˆ(y y )
min
y
 
 
  

                          (4.1) 
where iy  is the mean value of experimental data point i , iyˆ  is the simulated value, and n  is the 
total number of experimental data points. With this computational signaling template, I quantify 
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the integrated response, total receptor phosphorylation over time [375], [376], at each 
compartment, normalized to the membrane integrated response (Table 4.2). 
4.4.2 Model compartmentalization.  
The model contains eight compartments representing standard receptor endocytosis 
[377]–[380]: (i) ligand-membrane receptor binding, (ii) ligand and receptor internalization via 
endocytic vesicles, (iii) endocytic vesicle fusion into early endosomes, (iv) early endosome 
recycling to the membrane, (v) early endosomal maturation into late endosomes, (vi) late 
endosome trafficking to lysosomes for degradation, (vii) early endosome and lysosome 
trafficking to the nucleus. I assume all compartments, except for the extracellular space, are 
spherical (Table 4.1). I assume that recycling endosomes are the same size as endocytic vesicles. 
Furthermore, I assume that lysosomes are the same size as late endosomes. I model the 
extracellular space volume as 0.5 cm
3
, shared equally between 2·10
5
 cells, based on typical 
culture conditions in 24-well plates [381]. The cytoplasm volume is included for reference only; 
I assume no ligands or receptors are available within the cytoplasm (Table 4.1). 
4.4.3 Ligand-receptor interactions.  
In all model compartments (Fig 4.1), I employ generalized ligand-receptor interactions 
using the following chemical reactions: 
L-R
L-R
kon
koff
L+R L:R                    (4.2) 
kp
kdp
L:R L:pR                  (4.3) 
L-Rkoff L+RL:pR                               (4.4) 
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where L is the ligand (M), R is the unphosphorylated receptor (M), pR is the phosphorylated 
receptor (M), semicolon indicates bound proteins, konL-R is the ligand-receptor on-rate, koffL-R is 
the ligand-receptor off-rate, kp is the receptor phosphorylation rate (1·10
-2
 s
-1
 [159]), and kdp is 
the receptor dephosphorylation rate (1·10
-3
 s
-1
 [159]). I assume the receptor phosphorylation and 
dephosphorylation rate are the same for all eight RTKs, and remain the same across all model 
compartments. Each compartment has additional trafficking or degradation reactions (Appendix 
B, Table B.1). 
4.4.4 Ligand-receptor interaction kinetics.  
The ligand-receptor dissociation constant depends on compartment pH (Table 4.1) [378], 
[382], [383]. Ligand-receptor interactions are strongest at pH 7.4, typical pH of the extracellular 
space, cytoplasm, and nucleus [384], but weaken as pH decreases [385]. Ligand-receptor 
dissociation constants typically increase 2- to 3-fold as pH decreases from 7.4 to 6.0 [385], 
[386], corresponding to early endosome pH [378]. At pH 5.0 in late endosomes [378], 
dissociation constants increase ~10-fold [386]. Ligand-receptor interactions no longer occur 
below pH 5.0, corresponding to lysosomes [378]. I fit the ligand-receptor off-rate as an 
exponential function to these average pH values by 
0.96 pH
offk = 1.21 e
                                                         (4.5) 
where pH < 5.0 has an infinite off-rate allowing no ligand-receptor interactions (Table 1). 
Similar pH mediated ligand-receptor kinetics have been constructed for EGF-EGFR interactions 
in early endosomes [327], [387].  
4.4.5 Defining ligand and receptor concentrations.  
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All cell receptors are initially localized to the cell membrane and all ligands are localized 
extracellularly (Table 4.2). Receptor and ligand concentrations are in units of molecules/cell, 
using concentration conversions from mass/volume to moles/volume as necessary using the 
ligand molecular weight: Ang2: 70 kDa [388], EGF: 74 kDa [389], FGF-2: 18 kDa [390], IGF-1: 
7.6 kDa [391], PDGF-AA: 30 kDa [392], PDGF-BB: 24 kDa [392], VEGF-A: 45 kDa [393]. 
4.4.6 Comparing receptor phosphorylation within endocytic vesicles to membrane.  
To compare endocytic vesicle to membrane receptor signaling, I model endocytic 
vesicles and membranes in isolation: no ligand, receptor, or ligand-receptor complex trafficking 
occurs. This ensures receptor phosphorylation is solely dependent on compartment volume. I 
assume one ligand for each receptor; for Tie2, which has 1,800 membrane receptors (Table 4.2) 
[328], this equates to 1,800 (84 pg/mL or 1.2 pM) extracellular Ang2 molecules, within the 
measured serum range (Table 4.2). I assume a single endocytic vesicle contains 5 receptors 
[394]–[396], giving 5 ligand molecules (1.1 mg/mL or 16 µM) in a single endocytic vesicle. 
When simulating all 1,800 receptors associated within endocytic vesicles, I model 5 receptors 
per endocytic vesicle, giving 360 endocytic vesicles total. 
4.4.7 Correlation analyses.  
The correlation analyses between compartment receptor signaling and RTK parameters is 
performed in OriginLab. I assume a lognormal fit between receptor signaling and RTK 
parameter to calculate the R
2
 fit, for all compartments. I focus on nuclear signaling for this 
correlation analysis as it provides the most variable compartment receptor signaling across the 
eight RTKs (Table 4.2), thus best representing how the RTK parameters mediate receptor 
signaling 
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4.5 Figures and Tables 
 
Figure 4.1: RTK endocytosis signaling template.  
Ligand-receptor interactions and trafficking occur across seven compartments (C1-C8), defined by their 
volume, pH, and ligand-receptor kinetics (Table 4.1). Rate parameters describing the transitions between 
intracellular compartments are also given. 
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Figure 4.2: RTK phosphorylation primarily occurs within endocytic vesicles early, and late 
endosomes late, after ligand stimulus.  
The percent of phosphorylated receptors relative to total cell receptors are given on (A) the cell 
membrane, (B) endocytic vesicles, (C) early endosomes, (D) recycling endosomes, (E) late endosomes, 
(F) lysosomes, and (G) in the nucleus. The activation time constant (𝜏a, time from ligand stimulus to 
63.2% max phosphorylation) and decay time constant (𝜏d, time from max phosphorylation to 36.8% max 
phosphorylation) in minutes are also given for each compartment. (H) Phosphorylated receptor 
localization relative to total cell receptors at 5, 60, 120, 180, and 240 minutes after ligand stimulus.  
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Figure 4.3: Endocytic vesicles facilitate high, sustained receptor phosphorylation.  
(A) Schematic showing the three simulations cases. (B) Receptor phosphorylation versus time was 
simulated on the cell membrane, on a single endocytic vesicle, or when all receptors were contained on 
endocytic vesicles. (C) The integrated responses, area under the curve, at 5 minutes, 1 hour and 2 hours 
are given for each case.  
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Figure 4.4: Nuclear translocation requires a late endosome pathway.  
Percent total cell receptors translocated to the nucleus when endocytic pathways are blocked for 4 hours 
following ligand stimulus. Inhibited pathways involve receptor movement from the early endosomes and 
late endosomes (Fig 4.1). These pathways are the recycling pathway (blue line), early endosomes to 
nucleus (green line), early endosomes to late endosomes (magenta line), late endosome to nucleus (red 
line), and the degradation pathway (cyan line). 
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Figure 4.5: Signaling compartmentalization is directed by extracellular ligand concentration.  
The percents of total receptor signaling associated with (A) the membrane, (B) endocytic vesciles, (C) 
early endosomes, (D) late endosomes, and (E) nucleus were quantified with altered Ang2-Tie2 
parameters, chosen as representative for all RTKs. Recycling endosome and lysosome based receptor 
signaling are not included as they account for < 0.01% total receptor signaling. The four parameters 
changed are: receptor level (black line), ligand concentration (red line), ligand-receptor on-rate (blue), and 
ligand-receptor off-rate (green).  
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Figure 4.6: Nuclear signaling across RTKs is directed by extracellular ligand concentration.  
Nuclear signaling amongst the 8 RTKs was fit to the following RTK parameters: (A) receptor level, (B) 
extracellular ligand concentration, (C) ligand-receptor dissociation constant, and (D) complex level, 
defined as the product of extracellular ligand concentration and membrane receptor level divided by the 
ligand-receptor dissociation constant. The R
2
 goodness of fit, using a lognormal fit assumption, is given 
for each RTK parameter.  
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Table 4.1: Model compartment parameters.  
Compartment Spherical 
Diameter 
Volume 
(cm
3
) 
pH kon 
(1/molecules·s) 
koff 
(1/s) 
Extracellular Space - 2.5·10
-6 
7.4 6.6·10
-9
 1.0·10
-3
 
Cytoplasm 18 µm
a 
1.6·10
-9
 7.4 - - 
Endocytic Vesicle 100 nm
b
  5.2·10
-16
 7.0 3.2·10
1
 1.5·10
-3
 
Early Endosome 1 µm
c 
5.2·10
-13
 6.0 3.2·10
-2
 3.8·10
-3
 
Recycling 
Endosome 
100 nm
d
  5.2·10
-16
 6.4 3.2·10
-2
 2.6·10
-3
 
Late Endosome 2 µm
e 
4.2·10
-12
 5.0 4.0·10
-3
 1.0·10
-2
 
Lysosome 2 µm
e 
4.2·10
-12
 4.5 0 1.0·10
2
 
Nucleus 14 µm
f 
1.4·10
-9
 7.4 1.2·10
-5
 1.0·10
-3
 
Compartments are defined by their spherical diameter, volume, pH, and ligand-receptor kinetics as 
shown. All compartments are assumed spherical except for the extracellular space. Note that koff rates are 
regulated by pH and the kon rates by compartment volume. References for diameters are given in the 
footnotes.
 
a[397]; b[398], [399]; c [400]; d[398], [399]; e[400]; f[401]. 
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Table 4.2: Compartment integrated responses for various RTKs.  
  Ang2-Tie2 EGF- 
EGFR 
FGF2-
FGFR1 
IGF1-
IGFR1 
PDGFAA-
PDGFRβ 
PDGFBB- 
PDGFRα 
VEGFA-
VEGFR1 
VEGFA-
VEGFR2 
 
P
ar
am
et
er
s 
Receptors/cell 
a 
1.8·10
3 d 
5.0·10
4
 
f 
2.8·10
4
 
i 
2.5·10
4
 
a 
5.3·10
4 a 
5.1·10
3 o 
2.7·10
3 o 
2.0·10
3
 
kon (M
-1
s
-1
) 
b 
6.0·10
3
 
d 
3.0·10
7
 
g 
9.6·10
4
 
j 
2.7·10
5
 
l 
8.8·10
3
 
l 
7.8·10
6 o 
3.0·10
7 o 
1.0·10
7
 
koff (s
-1
) 
b 
6.1·10
-4 d 
3.8·10
-3 g 
5.9·10
-3
 
j 
1.2·10
-3 l 
1.5·10
-4 l 
7.6·10
-3
 
o 
1.0·10
-3 o 
1.0·10
-3 
Ligand in Serum 
(pg/mL) 
c 
1865
 e 
917
 h 
2.2
 k 
1.65·10
5 m 
1769
 n 
8506 
h 
160
 h 
160
 
In
te
g
ra
te
d
 
re
sp
o
n
se
 r
el
at
iv
e 
to
 m
em
b
ra
n
e 
Membrane 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Endocytic Vesicle 90 84 386 75 57 73 76 80 
Early Endosome 9.2 4.2 10 2.7 8.9 2.4 8.0 8.4 
Recycling Endosome 8.8·10
-2
 3.8·10
-2
 9.8·10
-2
 2.3·10
-2
 8.7·10
-2
 1.9·10
-2
 7.6·10
-2
 8.0·10
-2
 
Late Endosome 54 39 108 27 41 23 52 55 
Lysosome 1.6·10
-4
 1.2·10
-4
 3.2·10
-4
 8.1·10
-5
 1.2·10
-4
 6.8·10
-5
 1.6·10
-4
 1.6·10
-4
 
Nucleus 9 47 17 38 16 35 36 33 
 Total membrane 
integrated response 
(p-Receptor·time) 
 
8.9·10
2
 
 
7.7·10
3
 
 
1.5·10
1
 
 
1.1·10
4 
 
4.7·10
4
 
 
2.3·10
3
 
 
1.6·10
3
 
 
1.1·10
3
 
Integrated responses in each compartment, relative to the membrane, in addition to interaction kinetics and receptor levels, are given for various 
RTKs. Interaction kinetics are given for pH = 7.4. Trafficking kinetics are kept the same for every RTK. Ligand concentrations are taken from 
serum levels. The total membrane integrated response over 4 hours after ligand stimulus is given for each RTK. 
 
a[328]; b[332]; c[402]; d[327]; e[403];  f[333]; g[334]; h[404]; i[330]; j[331]; k[405]; l[329]; m[406]; n[407]; o[178] 
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APPENDIX A: SUPPLEMENTARY ADAPTER MODELING METHODS 
A.1 Computational methods 
A.1.1 Obtaining adapter protein initial concentrations.  
Adapter initial concentrations in human umbilical vein endothelial cells (HUVECs) were 
obtained from Western blot data (Appendix A, Table A.1). I quantified the adapter intensity, and 
the intensity of a separate protein that had a known concentration, with ImageJ. The background 
intensities were measured and subtracted from the adapter known protein intensities. I 
normalized the adapter and known protein intensities to their respective control loading proteins. 
I calculated the initial adapter concentration as follows: 
adapter-background control-background0
0 protein-background control-background
/
/
I I[adapter]
=
[protein] I I
                      (A.1) 
where 0[adapter]  is the initial adapter concentration, 0[protein] is the known protein 
concentration, and I  is the intensity. This is a standard technique for initializing and validating 
computational models [159], [408]–[410]. 
A.1.2 Obtaining receptor-adapter interaction rates.  
Rates for VEGFR-adapter interactions are obtained from isothermal titration calorimetry 
or surface plasmon resonance experiments (Appendix A, Table A.2). If VEGFR-adapter specific 
interaction kinetics are unavailable, I use the kinetics between the adapter SH2 domain and a 
phosphorylated tyrosine kinase fragment. I assume adapters bind all VEGFR tyrosine sites with 
the same rate. Forward rates are implemented in cell/(molecule s) , using a conversion factor of 
1 121(M s) 1.66 10 cell/(molecule s)     , based on an assumed 1 pL cell volume.  
A.1.3 Modeling adapter phosphorylation and dephosphorylation.  
I assume all adapter phosphorylation rates (kp) are 0.01 s
-1
, so adapter phosphorylation is 
only dependent on VEGFR interaction kinetics. To account for adapter dephosphorylation, I 
model phosphatase binding to phosphorylated adapters and subsequent adapter 
dephosphorylation. I assume all adapters are dephosphorylated by a generalized protein tyrosine 
phosphatase non-receptor type (PTPN) phosphatase [411]. Furthermore, I assume that the PTPN 
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has the same binding kinetics for every adapter, and that the PTPN concentration is sufficiently 
high to not limit adapter dephosphorylation (Appendix A, Table A.2).  
A.1.4 Adapter contribution to overall cell response.  
The contribution of each adapter to proliferation and migration were obtained from 
previous experimental studies (Appendix A, Table A.3). In these experiments, each adapter was 
inhibited individually, and the percent of endothelial cell proliferation or migration inhibited in 
response was quantified. I assume for all experiments that the VEGF and drug treatments 
saturated all cells present. To calculate overall predicted cell response in my simulations, I weigh 
and sum the response contribution of each adapter as follows: 
12
1
,cell R i i
i
PR w

                                             (A.2) 
where 
cellR  is the overall cell response (proliferation or migration), ,R iw  is the amount of 
regulation adapter i  gives to that response, and 
i
P  is the phosphorylation of adapter i . The adapter 
weights are determined through by solving the linear problem  
S w ep R R       (A.3) 
Here, wR  is a vector containing the weights each adapter contributes to the cell response cellR . 
eR  is a vector containing the experimental cell responses, relative to the no inhibition case 
(Appendix A, Table A.3). Sp  is a matrix containing the model predicted phosphorylated adapter 
integrated responses, for each inhibition scheme. Lastly, the weights for proliferation and 
migration were normalized such that the migration weights summed to one. As these 
experimental drug treatments look at VEGF signaling in HUVECs as a whole, i.e. signaling 
contributions from VEGFR1 and VEGFR2, I use both receptors in the drug treatment 
simulations.  
A.1.5 Goodness of fit tests.  
Models were validated against published empirical data [412]–[416] by calculating the 
chi-squared value  2χ  (Appendix A, Fig A.1). 2χ  is calculated as follows: 
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 
2
2
1
χ
i
i
N
i
i
y f
f

        (A.4)  
where 
iy  is the empirical measurement at index i , if  is the simulated value, and N is the total 
number of empirical measurements. Goodness-of-fit was determined by testing the hypothesis 
that model predicted adapter phosphorylation differs from experimental adapter phosphorylation 
at the 0.05 significance level. The hypothesis is rejected, which is interpreted as the model 
accurately predicting experimental adapter phosphorylation, based on the degrees of freedom 
(df): 
2χ 0.103  for df = 2 (Appendix A, Fig A.1F), 2χ 0.352  for df = 3 (Appendix A, Fig 
A.1E), 
2χ 0.711  for df = 4 (Fig 3.3B-C; Appendix A, Fig A.1A-B, Fig A.1D), 2χ 1.145  for 
df = 5 (Fig 3.3A), and 
2χ 2.167  for df = 7 (Appendix A, Fig A.1C) [253].  
A.1.6 Modeling adapters binding specific VEGFR tyrosine sites.  
I assume that multiple adapters can bind a single receptor if the combined size of the 
adapters is smaller than the available space between tyrosine sites (i.e. the adapters have enough 
room to bind). To determine what adapter-tyrosine site distributions are possible, I use three 
pieces of information: (1) the specific tyrosine sites each adapter binds (Appendix A, Table A.4), 
(2) the size of each adapter (Appendix A, Table A.5), and (3) the space between each tyrosine 
site. These measurements were performed as follows: 
A.1.7 Determining adapter sizes.  
Adapter protein sizes were determined by measuring their crystal structures (Appendix A, 
Table A.5). To determine the length each adapter blocks on VEGFR1, the intracellular domain of 
VEGFR1 was assumed to be 1-dimensional (in the y-direction). Adapter protein crystal 
structures were then oriented such that they bound, via their SH2 domain, to the 1-dimensional 
VEGFR1. The largest y-direction size of the crystal structure was then measured. I further 
assume tyrosine sites are bound by the center of adapter proteins, such that half the adapter 
protein blocks VEGFR1 in the +y-direction and the other half blocks VEGFR1 in the –y-
direction. For example, if an adapter protein is 30 Å, it blocks all tyrosine sites within 15 Å of 
the tyrosine site it is bound to (Fig 3.1).  
A.1.8 Determining distance between VEGFR1 tyrosine sites.  
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To determine the distance between VEGFR tyrosine sites, I measured the average 
distance between amino acids in the VEGFRs tyrosine kinase domain crystal structure (Fig 3.1A-
B). I oriented the tyrosine kinase domain crystal structure to match my 1-dimensional VEGFR 
assumption; if the crystal structure contained multiple kinase domains, the tyrosine binding sites 
fall on a vertical line. The tyrosine kinase domain was measured, and that length was divided by 
the number of amino acids within the crystal structure to give the distance between individual 
amino acids. The distance between individual amino acids is multiplied by the number of amino 
acids between VEGFR tyrosine sites to give the distance between VEGFR tyrosine sites. For 
example, the distance between individual amino acids in VEGFR1 was measured as 0.171 
Å/amino acid, so the distance between tyrosine sites Tyr
1242
 and Tyr
1333
 is 15.6 Å.  
A.1.9 Metrics for model analyses.  
Cell response was predicted by quantifying two metrics obtained from model 
simulations: integrated response and amplitude. The integrated response is the area under the 
phosphorylation versus time curve, while phosphorylation amplitude is simply the peak 
phosphorylation an adapter reaches [375], [376]. These metrics are commonly used to quanitfy 
total signal propagation and signal propagation speed, respectively [375]. For example, Oyarzún 
et. al. showed that integrated EGFR responses scales linearly with applied ligand stimulus, 
suggesting that total signal propagation linearly increases with ligand concentration [417]. 
Likewise, Schilling et. al. found that CFU-E cell proliferation is directly correlated with 
integrated ERK response [376]. Conversely, Kumar et. al. found that quantifying these metrics 
predicts the cell response itself; the Akt phosphorylation amplitude directs apoptosis, whereas 
Akt integrated response directs proliferation [375]. Therefore, integrated response and 
phosphorylation amplitude of signaling molecules allow the cell response to be predicted.  
To compare a single adapter binding VEGFR1 in a tyrosine site independent manner to 
multiple adapters binding specific VEGFR1 tyrosine sites, I use the fractional change metric 
[418], given by: 
2 1
1
1


( )x x
x
                 (A.5) 
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where 
1
x  is the value of interest (adapter activation or cell response) with a single adapter 
binding VEGFR1, and 
2
x  is the corresponding value with multiple adapters binding specific 
VEGFR1 tyrosine sites. A fractional change of 1 means the value is the same for both adapter 
binding motifs. A fractional change > 1 indicates the value is greater given site specific adapter 
binding, whereas a fractional change < 1 indicates the comparison value is smaller in the second 
model.  
A.2 Experimental Methods 
A.2.1 Quantifying protein phosphorylation.  
RAW macrophages were seeded into a 96-well plate and grown to ~80% confluence. The 
cells were then serum starved overnight with DMEM supplemented with 0.5% FBS and 1% PS, 
and pretreated with any inhibitor overnight: 100 nM Wortmannin (Anti-PI3K, IC50 = 3 nM), 10 
µM U73122 (Anti-PLCɣ, IC50 = 1 µM), or 6 µM Imatinib Mesylate (Anti-Abl, IC50 = 0.6 µM). 
Cells were then stimulated with VEGF-A164 (50 ng/mL) for various time periods, and stimulation 
was stopped by washing the cells with ice cold TBS. Cells were fixed, quenched, blocked, and 
incubated at 4
o
C overnight with primary antibodies specific for phosphorylated Tyr
467/199
 PI3K, 
total PI3K, phosphorylated Tyr
783
 PLCɣ, total PLCɣ, phosphorylated Tyr
245
 Abl, or total Abl. 
Corresponding HRP-conjugated secondary antibodies were added to the cells, treated with 
substrate, and absorbance in each well was read at 450 nm to measure protein concentration. 
Experiments were independently carried out in triplicate. Data is represented as the mean 
phosphorylated over mean total protein (p/t) ratio ± standard error of the mean (SEM) for each 
treatment type and treatment time; here SEM is the sum of the phosphorylated and total protein 
SEMs. The (p/t) ratio given inhibitor treatment specific to the protein of interest was subtracted 
as background for each treatment time. For example, the PI3K (p/t) ratio given 30 minutes of 
VEGF stimulation is subtracted by the PI3K (p/t) ratio given 30 minutes of VEGF + Wortmannin 
stimulation. 
A.2.2 Cell migration assays.  
RAWs were seeded into a 12-well plate and grown to ~90% confluence. The cells were 
then serum starved overnight. The monolayer was then scratched with a 100 µL pipette tip and 
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washed once with PBS to remove floating cells. After the scratch, wells were treated with 750 
µL of the serum starved growth factor media containing VEGF-A164 (50 ng/mL), 10 µM 
Wortmannin, 10 µM U73122, 10 µM Imatinib Mesylate, or a combination of VEGF-A164 and an 
inhibitor. Images of the wounded cell monolayer were taken using a microscope at 0 h and 24 h 
after scratching. All experiments were independently carried out in triplicate. Cell migration was 
quantified as the number of cells contained within the total gap area relative to the number of 
cells immediately after the scratch. Cells were counted within the wound margin using ImageJ.  
A.2.3 Cell proliferation assays.  
RAWs were seeded into a 96-well plate and grown to ~50% confluence. The cells were 
then serum starved overnight. Culture medium was removed and cells were stimulated with fresh 
serum starved media containing VEGF-A164 (50 ng/mL), 10 µM Wortmannin, 10 µM U73122, 
10 µM Imatinib Mesylate, or a combination of VEGF-A164 and an inhibitor for 24 h. MTT was 
added to each well and incubated at 37
o
C for 4 hours. SDS-HCl solution was added to each well 
and incubated for another 4 hours at 37
o
C. The solution in each well was mixed with a pipette, 
and absorbance was read at 570 nm. All experiments were independently carried out in triplicate.  
A.2.4 Cell harvest for qFlow cytometry.  
RAWs were harvested when they reach 80- 90% confluency. Cellstripper
TM 
(Millipore, 
Billerica, MA), a non-enzymatic cell dissociation solution was applied to RAWs and incubated 
for 4-7 minutes at 37°C/5% CO2. Culture flasks were then tapped gently on the side to dislodge 
cell adherence. Dissociated RAWs were re-suspended in stain buffer (PBS, bovine serum 
albumin, sodium azide)[419], [420] and centrifuged at 500 ×g for 5 minutes. Supernatant was 
removed, and RAWs were re-suspended to a final concentration of 4 x 10
6
 cells/mL in stain 
buffer. 
A.2.5 Cell staining for flow cytometry.  
Cells were aliquoted at 25 µL (~1 x 10
5
 cells) to 5 ml polystyrene round-bottom tubes 
(BD Biosciences, New Jersey). Phycoerythrin (PE)-conjugated monoclonal antibodies were 
added to each tube at the optimal concentrations: 14 µg/mL for VEGFR1 and VEGFR2, 
determined by titration (Appendix A, Fig A.3B). A PE fluorophore is used as the basis of the 
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quantitative fluorescence measurements because its high extinction coefficient reduces error due 
to photobleaching, its fluorescence is not quenched by common biomolecules (e.g., antibodies), 
its fluorescence is independent of pH, and its size minimizes the possibility of multiple 
fluorophores conjugated to an antibody [421], [422]. Samples were incubated in dark for 40 
minutes and kept on ice. Samples were then centrifuged at 500 ×g with 4 mL stain buffer for 4 
minutes, and supernatant was removed. This washing step was repeated twice. Washed samples 
were resuspended in 200 – 300 µL stain buffer. For each culture flask, PE-conjugated antibodies 
were not added in 1 – 2 samples as controls, which undergo the same procedures as the labeled 
samples. Those unlabeled samples were used as control to eliminate cell auto-fluorescence and 
other background noises.  
A.2.6 Quantitative flow cytometry.  
The precision and accuracy of qFlow cytometry profiling has been rigorously tested 
[423]–[426]. Flow cytometry was performed on a LSR Fortessa (BD) Flow cytometer; BD 
FACSDIVA software was used for data acquisition, and FlowJo (TreeStar) software was used 
for data analysis. Sytox Blue (Invitrogen), a live/dead cell stain, was added to each sample at a 
final concentration of 5 μg/mL prior to placement in the flow cytometer. Sytox Blue was excited 
with a violet laser (407 nm) and its emission was collected using a 450/50 bandpass filter. 
Histograms of Sytox Blue fluorescence were plotted to identify the live cell population. PE was 
excited with a yellow-green laser (561 nm) and its emission was collected using a 582/15 
bandpass filter. Cells exhibiting little to no Sytox Blue fluorescence were gated as live cells. 
These gated cells were examined in a plot of forward scatter area (FSC-A) versus side scatter 
area (SSC-A) to gate the single-cell population. Next, 8,000 - 10,000 live single cells were 
collected from each tube based on the gating. For each receptor, 2 – 4 biological replicates were 
collected from 3 independent RAW cultures. 
A.2.7 Statistical analysis: ensemble-averaged data.  
Quantibrite PE beads (BD) were collected and analyzed under the same compensation 
and voltage settings as cell fluorescence data. Quantibrite PE beads comprise a combination of 
polystyrene beads conjugated with different density of PE molecules: low (474 PE 
molecules/bead), medium-low (5,359 PE molecules/bead), medium-high (23,843 PE 
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molecules/bead), and high (62,336 PE molecules/bead). A calibration curve that translated PE 
geometric mean to the number of bound molecules was determined using linear regression: y = 
mx+b, where x=log10
Number of PE molecules per bead
, y represented log10
PE geometric mean per bead
, and m and b 
represented the slope and intercept of the linear regression, respectively. Receptor levels for 
VEGFR1 and VEGFR2 were calculated as described previously [217].  
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A.3 Figures and Tables 
 
Fig A.1: PLC and PI3K are preferentially activated at Tyr
794
 on VEGFR1.  
The (A) integrated responses and (B) phosphorylation amplitudes of all adapters were quantified at each 
specific VEGFR1 tyrosine site at 60 minutes following VEGF stimulus.  
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Fig A.2: Both nonspecific and specific VEGFR1 site models predict relative adapter 
phosphorylation.  
Fitting model predicted adapter phosphorylation versus time to relative adapter phosphorylation through 
both VEGFR1 and VEGFR2. Experimental data was normalized so the maximum adapter 
phosphorylation is 1. Adapter phosphorylation was simulated for the same time length given by 
experimental measurements, and the maximum predicted adapter phosphorylation was normalized to 1. 
Model accuracy is tested with the Χ2 goodness-of-fit test [253]. References for experimental data are: (A) 
Crk [412], (B) Nck [412], (C) FAK [413], (D) PLCɣ [414], (E) Src [415], and (F) VRAP [416]. 
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Fig A.3: VEGFR1 and VEGFR2 quantification on RAWs.  
(A) Membrane VEGFR1 and VEGFR2 levels on RAWs were measured by quantitative flow cytometry. 
Data is represented as mean ± standard error of the mean. (B) Saturation curves of VEGFR1 and 
VEGFR2 antibodies on RAWs show that all receptors are labeled, ensuring accurate quantification. 
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Table A.1: Model protein concentrations.  
 
  
Protein 
Model 
concentration  
(molecules/cell) 
Experimental 
concentration  
(molecules/cell) 
Reference 
Protein 
 
Cell Line 
 
Cell Conditions 
 VEGFR1 9.90·10
2
 990       [328] - HUVEC Growth media (EGM-2) 
VEGFR2 1.89·10
3
 1890      [328] - 
 PTPN 8.00·10
4
 Estimated - - - 
B
o
th
 V
E
G
F
R
s 
 
Abl 
 
1.50·10
3
 
2.11·10
3 
    [412] 
1.20·10
3       
[427] 
1.18·10
3       
[428] 
VEGFR2 
VEGFR2 
Cav1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth media (M199) 
24 h serum starvation 
Growth media (EGM-2) 
Cav1 
 
2.41·10
3
 2.02·10
3
     [429] 
2.80·10
3       
[430] 
VEGFR2 
VEGFR2 
Growth media 
Growth media (EBM) 
c-Cbl 
 
1.19·10
3
 1.19·10
3       
[431] VEGFR2 Growth media 
Crk 
 
1.11·10
3
 1.48·10
3       
[412] 
7.42·10
2       
[432] 
VEGFR2 
FAK 
Growth media (M199) 
2 h serum starvation 
 
FAK 
 
1.38·10
3
 
1.76·10
3       
[433] 
1.53·10
3    
[434] 
8.43·10
2    
[435] 
VEGFR2 
VEGFR2 
VEGFR2 
2 h serum starvation 
6 h serum starvation 
24 h serum starvation 
Fyn 
 
8.97·10
2
 9.96·10
2    
[436] 
7.98·10
2       
[432] 
VEGFR2 
FAK 
24 h serum starvation 
2 h serum starvation 
 
GAP 
 
1.26·10
3
 
1.32·10
3    
[437]
  
 
1.09·10
3
   [438] 
1.38·10
3
   [439] 
VEGFR2 
VEGFR2 
VEGFR2 
24 h serum starvation 
Overnight serum starvation 
Overnight serum starvation 
Grb2 
 
7.10·10
2
 9.53·10
2
     [412] 
4.66·10
2     
[440] 
VEGFR2 
ALK1
a 
Growth media (M199) 
Growth media (EBM-2) 
 Nck 
 
7.07·10
3
 3.23·10
3     
[441] 
1.09·10
4
    [442] 
PLCɣ 
VEGFR2 
6 h serum starvation 
18 h serum starvation 
 
PI3K
a
 
 
8.34·10
2
 
9.33·10
2     
[443] 
6.07·10
2     
[444] 
9.63·10
2     
[445] 
VEGFR2 
Src 
VEGFR2 
24 h serum starvation 
Growth media (DMEM) 
Growth media (M199) 
 
PLCɣ 
 
1.10·10
3
 
1.03·10
3     
[446] 
1.01·10
3     
[437]
       
1.25·10
3     
[414] 
VEGFR2 
VEGFR2 
GAP 
16 h serum starvation 
24 h serum starvation 
Overnight serum starvation 
 
Src 
 
1.62·10
3
 
1.99·10
3        
[433] 
1.48·10
3     
[434] 
1.38·10
3     
[447] 
VEGFR2  
VEGFR2 
VEGFR2 
2 h serum starvation 
6 h serum starvation 
Overnight serum starvation 
Sck 
 
1.35·10
3
 1.35·10
3     
[448]      VEGFR2 1 h serum starvation 
V
E
G
F
R
2
 
O
n
ly
 
Shb 
 
2.14·10
3
 2.14·10
3     
[449], 
[450]
b
 
GAP 20 min serum starvation 
Shc 
 
1.84·10
3
 1.40·10
3 
  [451]
     
2.28·10
3 
  [452]    
      
 
GAP 
VEGFR2 
Growth media 
Serum starvation 
VRAP 9.01·10
3
 9.01·10
2 
  [453] PLCɣ 16 h serum starvation 
Adapter, receptor, and phosphatase concentrations in HUVECs were obtained from the references 
provided. Adapter model concentrations are the mean of the experimental concentrations. Reference 
protein indicates the known protein concentration used to determine the adapter concentration. In cases 
where adapters are the reference protein, the model concentration was used as the known concentration. 
Cell line and conditions used for the experiment are given. 
 
aPI3K is modeled as the p85α domain 
bALK1 concentration in HUVECs was quantified by flow cytometry in [440]. 
cTo calculate the Shb concentration in HUVECs, the Shb/GAP ratio is assumed to be the same in HUVEC and Jurkat cells.  
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Table A.2: Computational model kinetics.  
 
  
Receptor 
VEGF-receptor 
forward rate  
(cell/molecule·s) 
VEGF-receptor 
reverse rate  
(1/s) 
Receptor 
phosphorylation 
rate 
 VEGFR1 1.81·10
-5
     1.00·10
-3
  [178]    Immediate
a 
 VEGFR2 6.02·10
-6
     1.00·10
-3
  [178] Immediate
a 
  
Protein  
Adapter-receptor 
forward rate  
(cell/molecule·s) 
Adapter-receptor 
reverse rate  
(1/s) 
Adapter 
phosphorylation 
rate (1/s) 
 
B
o
th
 V
E
G
F
R
s 
Abl 1.06·10
-7
     2.27·10
-3       
[454]  
 
 
 
 
 
 
 
0.01
c 
 
 
 
 
 
 
 
 
 
Cav1 2.47·10
-8
     1.76·10
-3       
[455] 
c-Cbl 8.30·10
-7
     5.00·10
-3       
[456] 
Crk 4.65·10
-8
     3.10·10
-3       
[457] 
FAK 5.50·10
-7
     1.00·10
-2       
[458] 
Fyn 1.28·10
-7
     1.00·10
-2     
[459] 
GAP 1.66·10
-6
     2.00·10
-1     
[327] 
Grb2 1.66·10
-5
     5.50·10
-1     
[327] 
 Nck 4.98·10
-8
     8.10·10
-1     
[460] 
PI3K 1.50·10
-6
     2.00·10
-2     
[158] 
PLCɣ 9.96·10-5     2.00·10-2     [255] 
Src 5.48·10
-7
     1.20·10
-3     
[461] 
Sck 3.32·10
-9
 1.00·10
-1         b
 
 
V
E
G
F
R
2
  Shb 3.32·10
-9
 1.00·10
-1         b
 
Shc 3.32·10
-9
 1.00·10
-1     
[462] 
VRAP 1.00·10
-7
 1.00·10
-2     
[453] 
A
ll
 
A
d
ap
te
rs
  
Protein 
Adapter-PTPN 
forward rate 
(cell/molecule·s) 
Adapter-PTPN 
reverse rate  
(1/s) 
PTPN 
dephosphorylation 
rate 
PTPN 8.10·10
-6
 1.63      [159] 3.39       [159] 
Adapter-receptor interaction rates were derived from the references provided. Forward and reverse rates 
for each adapter are from the same reference. Adapter-receptor interaction rates are assumed to be the 
same for VEGFR1 and VEGFR2. 
 
aVEGFRs are assumed to phosphorylate immediately upon VEGF binding. 
bDue to limited information, binding rates of Shb and Sck to VEGFRs are assumed to be the same as Shc, as these adapters are part of the same 
family. 
cPhosphorylation rate is assumed the same for all adapters.  
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Table A.3: Adapter contribution to cell proliferation and migration with VEGF treatment.  
 
Adapter 
 
% Proliferation 
Inhibition 
Inhibitor   % Migration 
Inhibition 
Inhibitor Inhibitor 
IC50 
Model 
Proliferation 
Weight 
Model 
Migration 
Weight 
Abl 59% [463] 
(HMVEC) 
STI571 
10 µM 
10% [463] 
(HMVEC) 
STI571 
10 µM 
0.8 µM 
[464] 
1.8·10-1 -8.0·10-2 
Cav1 -42% [465] 
(HUVEC) 
Cav1 
transfection 
46% [466] 
(HUVEC) 
siRNA - -6.5·10-2 3.3·10-1 
c-Cbl Negligiblea - Negligiblea - - 0 0 
 
Crk Negligiblea 
 
- 60% [467] 
(HUVEC) 
Mutation - 0 3.1·10-1 
FAK < 1% [468] 
(HUVEC) 
siRNA 30% [469] 
(HUVEC) 
siRNA - 0 1.5·10-2 
Fyn 15% [470] 
(HRMEC) 
siRNA -25% [470] 
(HRMEC) 
siRNA - 1.4·10-2 -2.1·10-1 
GAP 
 
63% [471] 
(HUVEC) 
Fasudil 
10 µM 
50% [471] 
(HUVEC) 
Fasudil 
10 µM 
1.2 µM 
[472]  
2.1·10-2 1.2·10-2 
Grb2 40% [473] 
(HUVEC) 
C90 
0.3 µM 
47% [473] 
(HUVEC) 
C90 
0.3 µM 
150 nM 
[474] 
1.3·10-1 1.1·10-1 
Nck Negligiblea 
  
- 
 
40% [475] 
(HUVEC) 
shRNA - 0 5.1·10-2 
PI3K 28% [476] 
(HUVEC) 
LY294002 
10 µM  
48% [477] 
(HUVEC) 
LY294002 
10 µM 
0.5 µM 
[478] 
1.1·10-1 1.7·10-1 
PLCɣ 50%
 [479] 
(HUVEC) 
U73122 
10 µM 
65% [477] 
(HUVEC) 
U73122 
6 µM 
0.8 µM 
[480] 
1.9·10-1 2.5·10-1 
Sck Negligiblea - Negligiblea - - 0 0 
 
Shb Negligiblea - Negligiblea - - 0 0 
Shc Negligible 
[481] 
shRNA Negligible 
[481] 
shRNA - 0 0 
Src 29% [482] 
(HUVEC) 
M475271 
3 µM 
68% [482] 
(HUVEC) 
M475271 
3 µM 
25 nM 
[483] 
5.8·10-2 1.7·10-1 
VRAP -9% [416] 
(HUVEC) 
siRNA 44% [416] 
(HUVEC) 
siRNA - -1.4·10-1 1.6·10-1 
Percent decrease in EC proliferation and migration when each adapter is inhibited, given by the provided 
references. Negative percentages indicate an anti-proliferative or anti-migratory role. The cell type, 
inhibitor concentration, and inhibitor IC50 are given. Proliferation and migration weights used to correlate 
adapter phosphorylation to cell response are given for each adapter. I assume that only c-Cbl 
phosphorylation contributes to the activation of cell degradation. 
 
HUVEC – Human umbilical vein endothelial cell; HMVEC – Human microvascular endothelial cell;  
HRMEC – Human retinal microvascular endothelial cell;  
aNot identified, I assume the adapter contribution is negligible to other adapters 
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Table A.4: Adapter-VEGFR tyrosine site interaction references.  
 
 VEGFR1  
Interaction 
Reference VEGFR1 
Interaction  
Reference VEGFR2 
Interaction 
Reference VEGFR2  
Interaction 
Reference 
Y794-PLCɣ [484] Y1213-Cav1 [485], 
[486]
g 
Y801-PLCɣ [484] Y1175-Abl [487] 
Y794-PI3K [488] Y1213-FAK [486], 
[489]
h 
Y801-PI3K [490] Y1175-Shc [158], 
[491], [492]
i 
Y1169-PLCɣ [493] Y1242-PLCɣ [484] Y951-PLCɣ [488], 
[494] 
Y1175-Shb [492] 
Y1169-GAP [495], 
[496]
a 
Y1333-PLCɣ [497] Y951-VRAP [416] Y1175-Sck [498] 
Y1169-Src [495], 
[496]
b 
Y1333-Nck [497], 
[499] 
Y1008-PLCɣ [500] Y1214-PI3K [499], [501]
j 
Y1169-Abl [495], 
[496], 
[502]
c 
Y1333-Crk [497] Y1059-PLCɣ [157], 
[503] 
Y1214-Fyn [486] 
Y1169-Sck [498], 
[504]
d 
Y1333-c-Cbl [505], 
[506] 
Y1059-Src [507] Y1214-Nck [486] 
Y1213-PLCɣ [497] - - Y1059-GAP [507] Y1214-FAK [508] 
Y1213-PI3K [509] - - Y1059-c-Cbl [507], 
[510] 
Y1214-Crk [467], 
[486]
k 
Y1213-Fyn [486] - - Y1175-PLCɣ [487], 
[511] 
Y1214-Src [486], [507] 
Y1213-Nck [499] - - Y1175-Src [507] Y1214-GAP [512] 
Y1213-Src [486], 
[513]
e 
- - Y1175-PI3K [490] Y1214-Cav1 [512], [514] 
Y1213-GAP [486], 
[515]
f 
- - Y1175-Grb2 [516] Y1305-FAK [508], [517] 
Y1213-Grb2 [497] - - Y1175-GAP [359], 
[518] 
- - 
References indicate were the adapter-VEGFR tyrosine site interaction was derived. These interactions are 
either empirically observed, or provide information leading to an assumed interaction. For example, 
showing an interaction between an adapter and an amino acid chain that correlates to a VEGFR tyrosine 
site. Several adapter-VEGFR interactions were also empirically observed without specifying the specific 
tyrosine site; assumptions for these tyrosine sites are given in the footnotes, with all references relating to 
the assumption in the table. 
 
a Assumed based on GAP interaction at VEGFR2-Y1175, and VEGFR1-Y1169 homology with VEGFR2-Y1175. 
b Assumed based on Src interaction at VEGFR2-Y1175, and VEGFR1-Y1169 homology with VEGFR2-Y1175. 
c Assumed based on Abl interaction at VEGFR2-Y1175, and VEGFR1-Y1169 homology with VEGFR2-Y1175. 
d Assumed based on Sck interaction at VEGFR2-Y1175, and VEGFR1-Y1169 homology with VEGFR2-Y1175. 
e Assumed based on Src interaction at VEGFR2-Y1214, and VEGFR1-Y1213 homology with VEGFR2-Y1214. 
f Assumed based on GAP interaction at VEGFR2-Y1214, and VEGFR1-Y1213 homology with VEGFR2-Y1214. 
g Assumed based on Cav1 interaction at VEGFR2-Y1214, and VEGFR1-Y1213 homology with VEGFR2-Y1214. 
h Assumed based on FAK interaction at VEGFR2-Y1214, and VEGFR1-Y1213 homology with VEGFR2-Y1214. 
i Assumed based on Shb interaction at VEGFR2-Y1175, and Shc homology with Shb. 
j Assumed based on PI3K interaction at VEGFR1-Y1213, and VEGFR2-Y1214 homology with VEGFR1-Y1213. 
k Assumed based on Nck interaction at VEGFR2-Y1214, and Crk homology with Nck. 
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Table A.5: Adapter sizes.  
 
Adapter
a 
Domain Crystal 
AA 
Total 
AA 
Size 
(Å) 
PDB 
Entry 
Reference 
Abl SH2 38-512 1130 31.34 3T04 [519] 
c-Cbl SH2, N-term 1-323 474 53.57 3VRR [520] 
Crk SH2 1-204 304 31.39 2EYY [521] 
FAK FA 891-1052 1052 33.55 4NY0 [522] 
Fyn SH2 143-248 537 33.97 1AOT [523] 
GAP SH2 341-446 1047 39.13 2GSB - 
Grb2 SH2 53-163 217 31.31 4P9V [524] 
Nck SH2 281-377 377 30.41 2CI9 [460] 
PI3K SH2 617-724 724 32.57 1H9O [525] 
PLCɣ SH2 545-790 1290 34.29 4FBN [526] 
Src SH2 144-252 536 32.76 4F5B [527] 
Shc
b 
SH2 147-311 583 37.28 1SHC [528] 
Sizes of each adapter protein used in the VEGFR1-adapter protein models. Note that entire crystal 
structures are rarely available, and so the domain each crystal structure contains is given. The segment of 
amino acids (AA) contained in the crystal structure is given compared to the total AA in the protein 
sequence. The Protein Data Bank and reference for each crystal structure are given if available. 
aNo crystal structure for VRAP or Cav1 available. I assume they have a 30 Å lower size limit. 
bNo crystal structures for Shb and Sck available. I assume they are the same size as Shc as they are part of the same family. 
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Table A.6: RAW macrophage adapter concentrations.  
 
Protein Model concentration  
(molecules/cell) 
Reference 
Protein 
Cell 
Line 
Cell  
Condition 
VEGFR1 4.82·10
3
  ± 1.12·10
2
 Measured RAW Growth media (DMEM) 
VEGFR2 1.77·10
3
  ± 1.32·10
2
 Measured 
PTPN 8.00·10
4
 Estimated - - 
Abl 3.20·10
3
 ± 5.92·10
2
     [529] FAK  
 
 
 
 
 
 
 
 
 
RAW 
 
 
 
 
 
 
 
 
 
 
 
Growth media (DMEM) 
Cav1 4.29·10
3
 ± 7.94·10
2
    [530] p38 Growth media (DMEM) 
c-Cbl 2.48·10
3
 ± 4.58·10
2
     [531] p38 Growth media (DMEM) 
Crk 2.71·10
3
 ± 5.00·10
2
     [529] FAK Growth media (DMEM) 
FAK 3.30·10
3
 ± 6.10·10
2
     [489] VEGFR1 Growth media (alpha-MEM) 
Fyn
a 
2.70·10
3
 ± 5.00·10
2
     [532] FAK Growth media (RPMI 1640) 
GAP 9.90·10
3
 ± 1.84·10
3
  [533] ERK Growth media 
Grb2 7.13·10
3
 ± 1.32·10
3
  [533] ERK Growth media 
Nck 3.80·10
3
 ± 7.02·10
2
  [534] VASP Growth media (alpha-MEM) 
PI3K 2.28·10
3
 ± 4.22·10
2
  [535] Akt Growth media (DMEM) 
 PLCɣ 2.28·103 ± 4.22·102  [536] IKBα Growth media (RPMI 1640) 
Sck
b 
2.00·10
3                          - - 
Shb
b 
2.00·10
3 - - 
Shc 1.08·10
4
 ± 2.00·10
3
  [533] ERK Growth media 
Src 2.61·10
3
 ± 4.82·10
2  
  [537] FAK Growth media (DMEM) 
VRAP
b 
2.00·10
3 - - 
Akt 2.28·10
3
 ± 4.22·10
2     
[538] p38 Growth media (DMEM) 
ERK 5.21·10
3
 ± 9.68·10
2     
[538] p38 Growth media (DMEM) 
IKBα 2.19·103 ± 4.04·102     [539] p38 Growth media (DMEM) 
p38 2.24·10
3
 ± 4.15·10
2     
[529] FAK Growth media (DMEM) 
VASP 2.38·10
3
 ± 4.40·10
2     
[540] IKBα Growth media (DMEM) 
Adapter, receptor, and phosphatase concentrations in RAW 264.7 macrophages were derived from the 
references provided. reference protein indicates the known protein concentration that was used to 
determine the adapter concentration. Concentrations for all reference proteins are provided. The cell line 
and conditions used for the experimental measurements are also given. For cell condition, starvation time 
and growth media is given, if available. Adapter concentrations are given as mean ± standard error of the 
mean, from the experimental measurement. 
 
aThe Fyn concentration was unavailable. Instead, I assume the Fyn concentration is equal to the Lyn concentration, as they are a part of the same 
family. 
bThe adapter concentration is unavailable. Since VRAP and Shb do not bind to VEGFR1, and I found Sck to not significantly direct VEGFR1 
signaling, their concentrations are not essential for determining VEGFR1 signaling. Thus, I assume these concentrations are 2.00·103 
molecules/cell, within the range of the other adapter concentrations.  
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APPENDIX B: SUPPLEMENTARY ENDOCYTOSIS INFORMATION 
B.1 Figures and Tables 
 
Figure B.1: Model trafficking parameters determined by fitting experimental data.  
Trafficking parameters were fit by comparing generalized receptor model results to experimental data 
[541]–[545]. Experimental data includes (A) percent total receptor internalized, (B) percent total receptor 
localized to the nucleus, (C) percent total receptor co-localization with early endosomes, (D) receptor co-
localization with early endosomes over time, (E) percent total receptor co-localization with late 
endosomes, and (F) receptor co-localization with late endosomes over time. 
 
176 
 
 
Figure B.2: Correlation analysis between RTK parameters and membrane signaling.  
Membrane signaling amongst the 8 RTKs was fit to the following RTK parameters: (A) receptor level, 
(B) extracellular ligand concentration, (C) ligand-receptor dissociation constant, and (D) complex level, 
defined as the product of extracellular ligand concentration and membrane receptor level divided by the 
ligand-receptor dissociation constant. The R
2
 goodness of fit, using a lognormal fit assumption, is given 
for each RTK parameter.  
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Figure B.3: Correlation analysis between RTK parameters and endocytic vesicle signaling.  
Endocytic vesicle signaling amongst the 8 RTKs was fit to the following RTK parameters: (A) receptor 
level, (B) extracellular ligand concentration, (C) ligand-receptor dissociation constant, and (D) complex 
level, defined as the product of extracellular ligand concentration and membrane receptor level divided by 
the ligand-receptor dissociation constant. The R
2
 goodness of fit, using a lognormal fit assumption, is 
given for each RTK parameter.  
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Figure B.4: Correlation analysis between RTK parameters and early endosome signaling.  
Early endosome signaling amongst the 8 RTKs was fit to the following RTK parameters: (A) receptor 
level, (B) extracellular ligand concentration, (C) ligand-receptor dissociation constant, and (D) complex 
level, defined as the product of extracellular ligand concentration and membrane receptor level divided by 
the ligand-receptor dissociation constant. The R
2
 goodness of fit, using a lognormal fit assumption, is 
given for each RTK parameter.  
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Figure B.5: Correlation analysis between RTK parameters and late endosome signaling.  
Late endosome signaling amongst the 8 RTKs was fit to the RTK parameters: (A) receptor level, (B) 
extracellular ligand concentration, (C) ligand-receptor dissociation constant, and (D) complex level, 
defined as the product of extracellular ligand concentration and membrane receptor level divided by the 
ligand-receptor dissociation constant. The R
2
 goodness of fit, using a lognormal fit assumption, is given 
for each RTK parameter.  
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Table B.1: Model implemented trafficking kinetics compared to previous endocytosis models.  
Parameter Implemented 
Rate 
VEGFR2
a
 
 
EGFR
b 
EGFR
c 
HER2
d 
kint (R) 1.5·10
-3
 1.6·10
-3
 5.0·10
-5
 0 1.7·10
-4
 
kint (pR) 1.0·10
-2
 1.7·10
-2
 5.0·10
-5
 3.5·10
-3
 7.2·10
-4
 
kdeg (R) 1.0·10
-4
 3.8·10
-4
 6.7·10
-4
 1.3·10
-4
 7.0·10
-5
 
kdeg (pR) 1.0·10
-4
 9.6·10
-2
 6.7·10
-4
 3.3·10
-4
 7.0·10
-5
 
krecEE (R) 1.0·10
-3
 7.8·10
-2
 5.0·10
-3
 5.3·10
-4
 1.1·10
-3
 
krecEE (pR) 1.0·10
-3
 9.4·10
-2
 0 3.3·10
-4
 1.1·10
-3
 
krecRE (R) 1.0·10
-2
 - - - - 
krecRE (pR) 1.0·10
-2
 - - - - 
kVCtoEE (R) 5.0·10
-5
 - - - - 
kVCtoEE (pR) 5.0·10
-4
 - - - - 
kEEtoRE (R) 1.0·10
-4
 - - - - 
kEEtoRE (pR) 1.0·10
-4
 - - - - 
kEEtoLE (R) 1.0·10
-2
 - - - - 
kEEtoLE (pR) 1.0·10
-3
 - - - - 
kEEtoN (R) 1.0·10
-4
 - - - - 
kEEtoN (pR) 1.0·10
-4
 - - - - 
kLEtoLS (R) 3.0·10
-5
 - - - - 
kLEtoLS (pR) 3.0·10
-4
 - - - - 
kLEtoN (R) 5.0·10
-5
 - - - - 
kLEtoN (pR) 5.0·10
-5
 - - - - 
Trafficking parameters for movement between each endocytic compartment. Different rates were fit for 
phosphorylated (pR) and unphosphorylated (R) receptors. Kinetic parameters used in several previous 
endocytosis models are given as a comparison. Dashes indicate rates that were not used in previous 
models. All rates are given in units of s
-1
. 
a[159]; b[327]; c[546]; d[547] 
 
